Lab Assignment 1

Yachen Zhao

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Abstract # | Title | Word Count | #Words (Verified by WordNet) | #Medical Words  (Verified by Bioportal / BioNLP)  All (Gene/Species/etc) |
| 1 | A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic. | 115 | cancer,leading,cause,cigarette,smoking,primary,cause,risk,across,same,number,are,at,greater,risk,are,at,lower,risk,developing,lung,specific,in,most,common,blood,modification,smoking,influence,internal,smoking,measured,by,urinary,nicotine,on,in,current,not,a,study,same,smoking,circulating,leukocyte,differ,by | HIV Disease D tobacco Species patients Species patients Species HIV Disease D HIV Disease D patients Species HIV Disease D patients Species patient Species patients Species men Species men Species women Species men Species women Species men Species women Species men Species women Species patients Species patient Species patients Species patients Species |
| 2 | Current and Former Smokers: Who Wants To Be Screened? | 58 | strong,evidence,effectiveness,tobacco,use,in,health,care,few,receive,cessation,advice,visiting,a,smoking,cessation,technology,in,outpatient,waiting,rooms,be,an,effective,strategy,potential,expose,almost,all,visiting,a,health,care,provider,physician,action | Lung cancer Disease LC Disease cancers Disease cancer Disease cancer Disease cancer Disease LC Disease LC Disease |
| 3 | High rates of Mycobacterium fortuitum isolation in respiratory samples from Iranian patients with suspected tuberculosis: is it clinically important? | 67 | cancer,screening,annual,tomography,reduce,specific,overall,mortality,in,selected,participation,key,successful,screening,sur,le,des,de,compliance,on,cancer,screening,compliance,nationwide,observational,are,used,assess,behavior,related,cancer,screening,in, | Mycobacterium fortuitum Species patients Species tuberculosis Disease D Mycobacterium fortuitum Species M. fortuitum Species patients Species tuberculosis Disease D M. fortuitum Species patients Species M. fortuitum Species lung disease Disease D patients Species men Species gastroesophageal disease Disease D Cystic fibrosis Disease D bacterial lung diseases Disease D lung cancer Disease D pulmonary diseases Disease D patients Species human immunodeficiency virus Disease HIV Disease ray Species lung disease Disease M. fortuitum Species infection Disease M. fortuitum Species infection Disease patients Species cystic fibrosis Disease infection DiseaseM. fortuitum Species patients Species HIV Disease |
| 4 | National Burden of Cancers Attributable to Secondhand Smoking in Indonesia | 28 | not,an,organism,rarely,isolated,respiratory,clinical,importance,still,not,fully,therefore,current, | Burden of Cancers Disease D people Species cancer Disease D burden of disease Disease D cancer Disease D cancers Disease D cancer Disease D cancers Disease D men Species pancreas cancer Disease D stomach cancer Disease D laryngeal cancer Disease women Species pancreas cancer Disease stomach cancer Disease bladder cancer Disease men Species woman Species lung cancer Disease cancer Disease cancer diseases Disease |
| 5 | The epidemiology of lung cancer. | 240 | high,prevalence,in,also,increase,number,people,as,smoke,many,health,will,bear,large,burden,but,research,on,cancer,related,secondhand,smoking,in,still,not,study,determine,number,secondhand,smoke,attributable,six,pancreas,burden,cancer,by,secondhand,smoking,using,research,epidemiological,research,prevalence,data,assurance,system,database,in,calculated,by,combining,both,data,secondhand,relative,risk,indicator,calculated,as,sum,years,life,lost,due,equivalent,healthy,years,lost,due,disability,on,men,in,pancreas,cancer,stomach,cancer,laryngeal,in,pancreas,cancer,stomach,cancer,bladder,cancer,burden,men,woman,lung,cancer,colorectal,cancer,6,cancer,due,secondhand,smoke,analyzed,in,research,can,be,used,as,a,basis,further,making,cigarette,prevention,control,in | lung cancer Disease lung cancer Disease tobacco Species tobacco Species lung carcinoma Disease passive smoke inhalation Disease infection Disease people Species marijuana Species nicotine Chemical |
| 6 | Prostacyclin and EMT pathway markers for monitoring response to lung cancer chemoprevention. | 131 | incidence,mortality,lung,cancer,decreasing,in,due,public,education,tobacco,control,but,are,increasing,elsewhere,in,world,related,commencement,tobacco,epidemic,in,various,in,developing,cigarette,smoking,by,far,most,common,risk,factor,lung,other,include,passive,smoke,residential,occupational,infection,genetic,predominant,disease,burden,currently,falls,on,minority,socioeconomically,disadvantaged,recent,legalization,marijuana,recreational,use,in,many,rapid,growth,commercially,available,electronic,nicotine,delivery,present,public,health,little,short,term,no,long,term,safety,data | Prostacyclin Chemical EMT Gene lung cancer Disease Lung cancer Disease cancer death Disease squamous lung carcinoma Disease bronchial dysplasia Disease prostacyclin Chemical iloprost Chemical Prostacyclin Chemical peroxisome proliferator-activated receptor gamma Gene PPARg Gene cancer Disease prostacyclin Chemical EMT Gene prostacyclin Chemical lung cancer Disease Human Species prostacyclin Chemical PGIS Gene mice Species urethane Chemical prostacyclin Chemical altered by tobacco carcinogens Disease prostacyclin Chemical PPARg Gene Cox- Gene bronchial dysplasia Disease prostacyclin Chemical lung cancer Disease prostacyclin Chemical lung cancer Disease |
| 7 | Cigarette Smoke-Induced Emphysema Exhausts Early Cytotoxic CD8+ T Cell Responses against Nascent Lung Cancer Cells. | 245 | cancer,leading,cause,cancer,death,worldwide,global,burden,be,reduced,through,application,development,lung,carcinoma,linked,high,grade,bronchial,histology,improved,in,former,in,a,trial,analogue,acts,through,receptor,gamma,reverse,epithelial,transition,promote,signaling,pathway,provide,response,lung,bronchial,epithelial,treated,cigarette,smoke,condensate,or,two,16,or,four,by,four,type,or,exposed,one,week,cigarette,smoke,or,one,injection,measured,potential,efficacy,in,identified,a,panel,altered,by,tobacco,inversely,affected,by,data,introduce,a,panel,potential,monitoring,interception,bronchial,dysplasia,progression,a,promising,approach,reduce,lung,cancer,mortality,in,a,high-risk,use,critical,success,in,future,clinical,lung,cancer | Emphysema Disease CD Gene Lung Cancer Disease Chronic obstructive pulmonary disease Disease inflammatory disorder Disease lung cancer Disease emphysema Disease chronic obstructive pulmonary disease Disease lung cancer Disease tumors Disease cancer Disease cancer Disease mice Species emphysema Disease Emphysema augmented the growth of cancer Disease emphysema tumor Disease PD-L Gene IDO Gene CD c Gene emphysema tumors Disease emphysema tumor Disease emphysema tumor Disease tumor Disease emphysema tumor Disease PD-L Gene IDO Gene PD-L Gene emphysema Disease emphysema tumor Disease human Species lung tumors Disease emphysema Disease lung cancer Disease inflammatory disorder Disease emphysema Disease cancer Disease emphysema Disease patients Species cancer Disease |
| 8 | Akt/PKB signaling regulates cigarette smoke-induced pulmonary epithelial-mesenchymal transition. | 131 | obstructive,pulmonary,disease,a,chronic,inflammatory,disorder,an,increased,incidence,lung,emphysema,component,chronic,obstructive,pulmonary,disease,greatest,proportion,lung,cancer,create,inflammatory,conditions,escape,immunological,control,growth,nascent,cancer,in,inflammatory,are,addressed,issue,by,cancer,in,cigarette,augmented,growth,cancer,an,effect,dependent,on,cytotoxic,early,exhaustion,transfer,in,emphysema,tumor,largely,irreversible,adoptive,transfer,restore,antitumor,numbers | Akt Gene pulmonary epithelial-mesenchymal transition Disease D lung cancer Disease D chronic obstructive pulmonary disease Disease D COPD Disease D lung cancer Disease D COPD Disease D MK- Chemical C Akt Gene tumors Disease D MK- Chemical C pulmonary EMT Disease D Akt Gene cigarette smoke extract Disease CSE Disease pulmonary epithelia Disease D mice Species CSE Disease mice Species Akt Gene MK- Chemical C mice Species TGF-b Gene a-SMA Gene vimentin Gene MMP- Gene MMP- Gene S A Gene E-cadherin Gene MK- Chemical C Akt Gene pulmonary epithelia Disease D Akt Gene CSE Disease TGF-b Gene Akt Gene mTOR Gene Akt Gene P MAPK Gene Akt Gene MK- Chemical C patients Species lung cancer Disease D COPD Disease D |
| 9 | Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes. | 90 | smoke,a,major,risk,factor,development,lung,cancer,chronic,obstructive,pulmonary,disease,transition,found,in,invasive,or,metastatic,in,lung,cancer,a,pan,in,clinical,solid,alone,at,but,it,have,synergistic,effects,applied,certain,molecular,working,mechanism,in,pulmonary,both,in,in | lung cancer Disease metastasis Disease cancer Disease death Disease lung cancer Disease tobacco Species lung cancer Disease Human Species adenocarcinoma Disease menthol Chemical tobacco Species b-catenin Gene lung cancer Disease metastasis Disease patient Species death Disease lung cancer Disease lung tumor Disease |
| 10 | Implication of C-type lectin receptor langerin and keratan sulfate disaccharide in emphysema. | 81 | transition,initial,step,enabling,metastasis,cancer,often,smoking,a,major,risk,factor,lung,there,still,widespread,use,conventional,tobacco,industry,transformed,by,introduction,electronic,have,lower,may,provide,a,investigate,ability,induce,an,in,lung,cancer,18/09/10 20:35:56 INFO MapOutputTrackerMasterEndpoint: MapOutputTrackerMasterEndpoint stopped! | C-type lectin receptor Gene langerin Gene sulfate Chemical CHEBI: emphysema Disease Keratan sulfate Chemical chronic obstructive pulmonary disease Disease COPD Disease lung inflammation Disease COPD Disease mouse Species steroid Chemical langerin Gene C-type lectin receptor Gene CLR Gene L Chemical langerin Gene COPD Disease inflammatory diseases Disease |

Abstract 1

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 46 | Lung, cancer, cause, death, cigarette, smoking, cause, malignancy, risk, groups, number, cigarettes, Hawaiians, whites, risk, Americans, risk, lung, cancer, DNA, methylation, CpG, sites, AHRR, F2RL3, blood, modification, smoking, status, influence, smoking, dose, nicotine, equivalents, NE, DNA, methylation, smokers, study, smoking, dose, leukocyte, DNA, methylation, patterns, race |
| POS:Verb | 19 | is, leading, is, differs, smoked, compared, are, are, developing, is, associated, measured, has, been, investigated, has, evaluated, circulating, differ |
| NER : Name | 0 |  |
| Triplet | 48 | [(tobacco use,is in,health care settings,1.0)]  [(few smokers,However receive,cessation advice,1.0), (smokers,visiting,hospital,1.0), (few smokers,visiting,hospital,1.0), (few smokers,receive,cessation advice,1.0), (smokers,However receive,cessation advice,1.0), (smokers,receive,cessation advice,1.0)]  [(could effective strategy,is with,potential expose,1.0)]  [(patients,passively exposing,them,1.0), (patients,exposing,them,1.0), (intervention,is in,waiting room of HIV outpatient clinic,1.0), (patients,spend in,room,1.0), (patients,spend in,waiting room,1.0)]  [(their face,would look to,15 years in future,1.0), (15 years,is in,future,1.0), (their face,would look to,15 years,1.0)]  [(We,placed tablet,app running on table in middle of waiting room of our HIV outpatient clinic,1.0), (app,running on,table in middle of room,1.0), (We,placed tablet,app running,1.0), (We,placed tablet,app running on table in middle,1.0), (app,running on,table in middle,1.0), (table,is in,middle of waiting room of our HIV outpatient clinic,1.0), (app,running on,table in middle of waiting room of our HIV outpatient clinic,1.0), (We,placed tablet,app running on table in middle of room,1.0), (We,placed tablet,app running on table,1.0), (We,placed tablet,app running on table in middle of waiting room,1.0), (app,running on,table in middle of waiting room,1.0), (app,running on,table,1.0), (We,placed,tablet,1.0), (app,running on,table in middle of room of our HIV outpatient clinic,1.0), (We,placed tablet,app running on table in middle of room of our HIV outpatient clinic,1.0)]  [(Those,complete,questionnaire,1.0), (Those,were,asked,1.0)]  [(RESULTS,visited During,19-day period,1.0)]  [(their,doctor,men,1.0)]  [(464 patients,of total is,62.3 %,1.0), (289,of total is,62.3 %,1.0)]  [(face-aging app,address,quitting at their appointment,1.0), (face-aging app,implemented in,waiting room,0.46308092758132374), (app,address,quitting at their subsequent appointment,1.0), (app,implemented in,waiting room,0.46308092758132374), (app,address,quitting,1.0), (face-aging app,address,quitting at their subsequent appointment,1.0), (patients,visiting,health care provider,0.7169231644655831), (app,address,quitting at their appointment,1.0), (face-aging app,implemented in,room,0.46308092758132374), (face-aging app,address,quitting,1.0), (app,implemented in,room,0.46308092758132374)] |
| Medical Words: Gene | 3 | … |
| … |  |  |

Abstract 2

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 24 | evidence, effectiveness, tobacco, use, health, care, settings, smokers, cessation, advice, hospital, smoking, cessation, technology, outpatient, rooms, strategy, change, patients, health, care, provider, physician, action |
| POS:Verb | 11 | is, addressing, receive, visiting, Implementing, waiting, be, expose, visiting, preluding, needed |
| NER : Name | 0 |  |
| Triplet | 1 | John,was playing with,dog |
| Medical Words: Gene | 53 | [(Lung cancer screening,reduce,specific mortality in populations,1.0), (Lung cancer screening,is with,annual low-dose computed tomography scans,1.0), (specific mortality,is in,selected populations,1.0), (Lung cancer screening,reduce,specific mortality,1.0), (Lung cancer screening,reduce,mortality,1.0), (annual low-dose computed tomography scans,with screening is,LCS,1.0), (Lung cancer screening,reduce,specific mortality in selected populations,1.0), (Lung cancer screening,reduce,mortality in populations,1.0), (Lung cancer screening,reduce,mortality in selected populations,1.0)]  [(participation,is key to,screening programs,1.0), (participation,is key to,successful screening programs,1.0), (participation,is,key,1.0), (participation,However is key to,successful screening programs,1.0), (participation,is,However key,1.0), (participation,However is key to,screening programs,1.0)]  [(EDIFICE nationwide surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE nationwide surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE nationwide surveys,assess,behavior,1.0), (behavior,related to,cancer screening programs in France,0.586438403410859), (EDIFICE nationwide observational surveys,assess,behavior,1.0), (EDIFICE nationwide observational surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE observational surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE nationwide observational surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE observational surveys,are,used,1.0), (behavior,related to,cancer screening programs,0.586438403410859), (EDIFICE observational surveys,assess,behavior related to cancer screening programs in France,1.0), (cancer screening programs,is in,France,1.0), (EDIFICE nationwide surveys,are,used,1.0), (EDIFICE nationwide surveys,assess,behavior related,1.0), (EDIFICE surveys,are,used,1.0), (EDIFICE surveys,assess,behavior,1.0), (EDIFICE observational surveys,assess,behavior,1.0), (EDIFICE nationwide observational surveys,are,used,1.0), (EDIFICE nationwide observational surveys,assess,behavior related,1.0), (EDIFICE surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE surveys,assess,behavior related,1.0), (EDIFICE observational surveys,assess,behavior related,1.0)]  [(we,identify,explanatory factors,1.0), (we,identify,factors associated,1.0), (we,identify,factors associated with intention participate,1.0), (we,identify,explanatory factors associated with intention participate in LCS program,1.0), (we,identify,explanatory factors associated,1.0), (we,identify,explanatory factors associated with intention participate,1.0), (we,identify,factors,1.0), (we,identify,factors associated with intention participate in LCS program,1.0)]  [(1463 respondents,is with,personal history of cancer,1.0), (former cigarette smokers,of 170 is,26.3 %,1.0), (current cigarette smokers,of 263 is,36.4 %,1.0)]  [(explanatory factors,differed between,current cigarette smokers,1.0), (explanatory factors,differed between,cigarette smokers,1.0), (factors,differed between,cigarette smokers,1.0), (factors,differed between,current cigarette smokers,1.0)] |
|  |  |  |

Abstract 3

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 28 | Lung, cancer, LC, screening, LCS, tomography, scans, mortality, populations, participation, screening, programs, EDIFICE, etude, sur, cancers, compliance, survey, cancer, screening, compliance, factors, surveys, behavior, cancer, screening, programs, France |
| POS:Verb | 9 | has, been, seen, reduce, selected, is, are, used, assess |
| NER : Name | 0 |  |
| Triplet | 190 | [(We,evaluated,respiratory samples from 6800 patients,0.8046867952576309), (Key findings,respiratory samples from,6800 patients with tuberculosis from May 2014 to May 2016,0.9761363852387743), (Key findings,samples from,6800 patients with tuberculosis from May 2014 to May 2016,0.9761363852387743), (We,evaluated,Key findings,0.8046867952576309), (We,respiratory samples from,6800 patients from May 2014,0.8475733259179079), (We,respiratory samples from,6800 patients from May 2014 to May 2016,0.8475733259179079), (We,evaluated,respiratory samples from 6800 patients with suspected tuberculosis from May 2014,0.8046867952576309), (We,respiratory samples from,6800 patients with suspected tuberculosis,0.8475733259179079), (We,samples from,6800 patients with tuberculosis,0.8475733259179079), (We,evaluated,respiratory samples from 6800 patients with suspected tuberculosis,0.8046867952576309), (Key findings,respiratory samples from,6800 patients with suspected tuberculosis,0.9761363852387743), (We,evaluated Key findings for,detection,0.8046867952576309), (Key findings,respiratory samples from,6800 patients from May 2014 to May 2016,0.9761363852387743), (We,evaluated,respiratory samples from 6800 patients from May 2014 to May 2016,0.8046867952576309), (We,evaluated,samples from 6800 patients with tuberculosis,0.8046867952576309), (We,evaluated,samples from 6800 patients with tuberculosis from May 2014 to May 2016,0.8046867952576309), (We,evaluated,samples from 6800 patients with suspected tuberculosis,0.8046867952576309), (Key findings,respiratory samples from,6800 patients with tuberculosis,0.9761363852387743), (Key findings,samples from,6800 patients with suspected tuberculosis from May 2014 to May 2016,0.9761363852387743), (We,evaluated,respiratory samples from 6800 patients with tuberculosis,0.8046867952576309), (Key findings,samples from,6800 patients from May 2014 to May 2016,0.9761363852387743), (Key findings,samples from,6800 patients from May 2014,0.9761363852387743), (Key findings,samples from,6800 patients with suspected tuberculosis from May 2014,0.9761363852387743), (We,evaluated,samples from 6800 patients,0.8046867952576309), (We,evaluated,samples from 6800 patients with suspected tuberculosis from May 2014 to May 2016,0.8046867952576309), (Key findings,respiratory samples from,6800 patients with suspected tuberculosis from May 2014 to May 2016,0.9761363852387743), (We,respiratory samples from,6800 patients,0.8475733259179079), (We,samples from,6800 patients with suspected tuberculosis from May 2014,0.8475733259179079), (We,evaluated,respiratory samples from 6800 patients with suspected tuberculosis from May 2014 to May 2016,0.8046867952576309), (6800 patients,is with,suspected tuberculosis,1.0), (We,evaluated,samples,0.8046867952576309), (Key findings,samples from,6800 patients,0.9761363852387743), (Key findings,samples from,6800 patients with tuberculosis,0.9761363852387743), (Key findings,respiratory samples from,6800 patients with tuberculosis from May 2014,0.9761363852387743), (We,evaluated,samples from 6800 patients from May 2014,0.8046867952576309), (Key findings,respiratory samples from,6800 patients with suspected tuberculosis from May 2014,0.9761363852387743), (We,evaluated samples for,detection,0.8046867952576309), (Key findings,respiratory samples from,6800 patients from May 2014,0.9761363852387743), (Key findings,respiratory samples from,6800 patients,0.9761363852387743), (We,evaluated samples for,detection of M. fortuitum,0.8046867952576309), (We,respiratory samples from,6800 patients with tuberculosis from May 2014 to May 2016,0.8475733259179079), (We,samples from,6800 patients from May 2014 to May 2016,0.8475733259179079), (Key findings,samples from,6800 patients with tuberculosis from May 2014,0.9761363852387743), (We,samples from,6800 patients with suspected tuberculosis,0.8475733259179079), (We,samples from,6800 patients,0.8475733259179079), (We,evaluated,samples from 6800 patients with tuberculosis from May 2014,0.8046867952576309), (We,respiratory samples from,6800 patients with suspected tuberculosis from May 2014 to May 2016,0.8475733259179079), (We,evaluated,samples from 6800 patients from May 2014 to May 2016,0.8046867952576309), (We,evaluated,respiratory samples from 6800 patients with tuberculosis from May 2014 to May 2016,0.8046867952576309), (We,respiratory samples from,6800 patients with tuberculosis,0.8475733259179079), (We,respiratory samples from,6800 patients with suspected tuberculosis from May 2014,0.8475733259179079), (We,samples from,6800 patients with tuberculosis from May 2014 to May 2016,0.8475733259179079), (We,evaluated,respiratory samples from 6800 patients from May 2014,0.8046867952576309), (We,samples from,6800 patients with suspected tuberculosis from May 2014 to May 2016,0.8475733259179079), (METHODOLOGY,evaluated for,detection of M. fortuitum using,1.0), (We,samples from,6800 patients with tuberculosis from May 2014,0.8475733259179079), (We,evaluated,respiratory samples,0.8046867952576309), (We,samples from,6800 patients from May 2014,0.8475733259179079), (We,evaluated Key findings for,detection of M. fortuitum,0.8046867952576309), (We,evaluated,samples from 6800 patients with suspected tuberculosis from May 2014,0.8046867952576309), (Key findings,samples from,6800 patients with suspected tuberculosis,0.9761363852387743), (We,respiratory samples from,6800 patients with tuberculosis from May 2014,0.8475733259179079), (We,evaluated,respiratory samples from 6800 patients with tuberculosis from May 2014,0.8046867952576309)]  [(40 patients,is with,M. fortuitum lung disease,1.0)]  [(35 patients,age of was,50.7 18.4 years,1.0), (patients,age of was,50.7 18.4 years,1.0)]  [(gastroesophageal disease,were,major symptoms,1.0), (gastroesophageal disease,were,symptoms,1.0), (gastroesophageal disease,were,presenting symptoms,1.0), (gastroesophageal disease,were,major presenting symptoms,1.0)]  [(Cystic fibrosis,were,diseases,1.0), (bacterial lung diseases,were,main pulmonary diseases,1.0), (lung cancer,were,main underlying pulmonary diseases,1.0), (lung cancer,were,main underlying diseases,1.0), (Cystic fibrosis,were,main underlying diseases,1.0), (lung diseases,were,underlying diseases,1.0), (other bacterial lung diseases,were,diseases,1.0), (other lung diseases,were,main pulmonary diseases,1.0), (fibrosis,were,main underlying pulmonary diseases,1.0), (Cystic fibrosis,were,underlying diseases,1.0), (fibrosis,were,diseases,1.0), (lung diseases,were,main pulmonary diseases,1.0), (other lung diseases,were,main underlying diseases,1.0), (other bacterial lung diseases,were,underlying pulmonary diseases,1.0), (bacterial lung diseases,were,underlying pulmonary diseases,1.0), (Cystic fibrosis,were,pulmonary diseases,1.0), (lung diseases,were,diseases,1.0), (other lung diseases,were,diseases,1.0), (other bacterial lung diseases,were,main diseases,1.0), (other bacterial lung diseases,were,main underlying diseases,1.0), (Cystic fibrosis,were,main diseases,1.0), (lung cancer,were,underlying diseases,1.0), (lung cancer,were,underlying pulmonary diseases,1.0), (bacterial lung diseases,were,pulmonary diseases,1.0), (lung diseases,were,underlying pulmonary diseases,1.0), (lung diseases,were,main underlying pulmonary diseases,1.0), (Cystic fibrosis,were,main underlying pulmonary diseases,1.0), (fibrosis,were,underlying pulmonary diseases,1.0), (lung diseases,were,pulmonary diseases,1.0), (other bacterial lung diseases,were,main underlying pulmonary diseases,1.0), (other bacterial lung diseases,were,underlying diseases,1.0), (other lung diseases,were,underlying diseases,1.0), (fibrosis,were,pulmonary diseases,1.0), (bacterial lung diseases,were,diseases,1.0), (fibrosis,were,main diseases,1.0), (Cystic fibrosis,were,underlying pulmonary diseases,1.0), (lung cancer,were,pulmonary diseases,1.0), (other lung diseases,were,main underlying pulmonary diseases,1.0), (lung cancer,were,main pulmonary diseases,1.0), (other lung diseases,were,underlying pulmonary diseases,1.0), (lung cancer,were,main diseases,1.0), (bacterial lung diseases,were,main underlying pulmonary diseases,1.0), (fibrosis,were,main underlying diseases,1.0), (bacterial lung diseases,were,main diseases,1.0), (other lung diseases,were,pulmonary diseases,1.0), (lung diseases,were,main underlying diseases,1.0), (lung cancer,were,diseases,1.0), (lung diseases,were,main diseases,1.0), (bacterial lung diseases,were,main underlying diseases,1.0), (fibrosis,were,underlying diseases,1.0), (Cystic fibrosis,were,main pulmonary diseases,1.0), (other bacterial lung diseases,were,pulmonary diseases,1.0), (other lung diseases,were,main diseases,1.0), (bacterial lung diseases,were,underlying diseases,1.0), (fibrosis,were,main pulmonary diseases,1.0), (other bacterial lung diseases,were,main pulmonary diseases,1.0)]  [(Five patients,were positive,immunodeficiency virus,1.0), (patients,were positive,HIV,1.0), (patients,were positive,human immunodeficiency virus,1.0), (patients,were,positive,1.0), (Five patients,were positive,HIV,1.0), (Five patients,were positive,human immunodeficiency virus,1.0), (patients,were positive,immunodeficiency virus,1.0), (Five patients,were,positive,1.0)]  [(common chest X-ray findings,were,reticulonodular opacities,1.0), (common chest X-ray findings,were,opacities,1.0)]  []  [(bacterium,infection in,patients,0.5013502698333384), (bacterium,transient infection in,patients,0.5013502698333384), (bacterium,transient infection such as,cystic fibrosis,0.5013502698333384), (bacterium,causes,transient infection,1.0), (patients,is with,underlying pulmonary conditions,1.0), (bacterium,infection in,patients with underlying conditions,0.5013502698333384), (colonization,transient infection such as,cystic fibrosis,0.9906240265190379), (bacterium,infection in,patients with pulmonary conditions,0.5013502698333384), (results,frequency of,M. fortuitum,0.9523594118421966), (bacterium,transient infection such as,fibrosis,0.5013502698333384), (colonization,transient infection in,patients with underlying pulmonary conditions,0.9906240265190379), (colonization,transient infection in,patients,0.9906240265190379), (results,high frequency of,M. fortuitum,0.9523594118421966), (bacterium,transient infection in,patients with pulmonary conditions,0.5013502698333384), (bacterium,infection in,patients with conditions,0.5013502698333384), (results,frequency in,respiratory samples,0.9523594118421966), (results,high frequency in,respiratory samples,0.9523594118421966), (high frequency,is in,respiratory samples,1.0), (bacterium,infection such as,cystic fibrosis,0.5013502698333384), (colonization,infection in,patients with underlying conditions,0.9906240265190379), (bacterium,causes,infection in patients with conditions,1.0), (bacterium,transient infection in,patients with underlying conditions,0.5013502698333384), (bacterium,causes,infection,1.0), (colonization,infection in,patients with conditions,0.9906240265190379), (colonization,transient infection such as,fibrosis,0.9906240265190379), (bacterium,infection in,patients with underlying pulmonary conditions,0.5013502698333384), (bacterium,causes,transient infection in patients with underlying pulmonary conditions,1.0), (colonization,transient infection in,patients with underlying conditions,0.9906240265190379), (bacterium,causes,transient infection in patients with pulmonary conditions,1.0), (bacterium,causes,colonization,1.0), (bacterium,causes,transient infection in patients,1.0), (bacterium,transient infection in,patients with underlying pulmonary conditions,0.5013502698333384), (results,high frequency in,samples,0.9523594118421966), (colonization,transient infection in,patients with pulmonary conditions,0.9906240265190379), (infection,is in,patients with underlying pulmonary conditions,1.0), (bacterium,causes,infection in patients with underlying pulmonary conditions,1.0), (bacterium,causes,transient infection in patients with conditions,1.0), (bacterium,causes,transient infection in patients with underlying conditions,1.0), (bacterium,causes,infection in patients with underlying conditions,1.0), (bacterium,causes,infection in patients,1.0), (colonization,infection such as,fibrosis,0.9906240265190379), (bacterium,transient infection in,patients with conditions,0.5013502698333384), (bacterium,infection such as,fibrosis,0.5013502698333384), (colonization,infection in,patients with pulmonary conditions,0.9906240265190379), (results,frequency in,samples,0.9523594118421966), (bacterium,causes,infection in patients with pulmonary conditions,1.0), (colonization,infection such as,cystic fibrosis,0.9906240265190379), (colonization,infection in,patients,0.9906240265190379), (colonization,transient infection in,patients with conditions,0.9906240265190379), (colonization,infection in,patients with underlying pulmonary conditions,0.9906240265190379)]  [(infection,is with,M. fortuitum,1.0), (infection,is,common,1.0), (infection,is,particularly common,1.0), (patients,is with,HIV,1.0)] |
| Medical Words: Gene | 3 | … |
| … |  |  |

Abstract 5

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 114 | Background, prevalence, smokers, Indonesia, number, people, secondhandsmokers, smoke, health, problems, cancer, Indonesia, numbercancer, burden, disease, research, cancer, smoking, Indonesia, exist.Therefore, study, number, smoke, fractions, SAFs, cancers, lung, bladder, stomach, pancreas, larynx, burden, cancer, smoking, inIndonesia, Disability, Adjusted, Life, Years, DALYs, indicator, Material, Methods, research, research, design, cancers, prevalence, data, Indonesianhealth, assurance, system, database, SAFs, data, smokingprevalence, risk, DALY, indicator, sum, years, life, prematuremortality, YLL, years, disability, YLD, Results, SAFs, proportion, SAFs, men, pancreas, cancer, %, stomach, cancer, %, cancer, %, women, pancreas, cancer, %, stomach, cancer, %, bladder, cancer, %, burden, priorities, men, woman, lung, cancer, andbladder, cancer, Conclusions, total, DALYs, cancer, diseases, smoke, thisstudy, DALYs, results, research, basis, policies, cigarette, prevention, control, Indonesia, |
| POS:Verb | 27 | is, increase, causes, including, bear, does, aimed, determine, caused, using, was, gained, is, calculated, combining, is, calculated, lost, lost, Based, were, were, analyzed, were, be, used, making, |
| NER : Name | 0 |  |
| Triplet | 23 | [(other risks,include,occupational exposures,1.0), (risks,include,passive smoke inhalation,1.0), (other risks,include,passive smoke inhalation,1.0), (risks,include,radon,1.0), (other risks,include,smoke inhalation,1.0), (risks,include,exposures,1.0), (other risks,include,susceptibility,1.0), (other risks,include,infection,1.0), (risks,include,smoke inhalation,1.0), (other risks,include,genetic susceptibility,1.0), (risks,include,residential radon,1.0), (risks,include,occupational exposures,1.0), (risks,include,susceptibility,1.0), (other risks,include,exposures,1.0), (risks,include,infection,1.0), (other risks,include,radon,1.0), (other risks,include,residential radon,1.0), (risks,include,genetic susceptibility,1.0)]  [(disease burden,falls on,minority populations,1.0), (disease burden,currently falls on,minority populations,1.0), (predominant disease burden,currently falls on,minority populations,1.0), (predominant disease burden,falls on,minority populations,1.0)]  [(recreational use,is in,many states,1.0)] |
| Medical Words: Gene | 3 |  |
| … |  |  |

Abstract 6

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 50 | 50: incidence, mortality, lung, cancer, US, decades, education, tobacco, control, policies, world, commencement, tobacco, countries, populations, world, cigarette, smoking, risk, factor, lung, carcinoma, risks, smoke, inhalation, radon, exposures, infection, susceptibility, disease, burden, minority, populations, people, US, legalization, marijuana, use, states, growth, nicotine, delivery, systems, ENDS, challenges, health, term, term, safety, data, |
| POS:Verb | 9 | is, decreasing, are, increasing, developing, is, include, falls, is, |
| NER : Name | 0 |  |
| Triplet | 99 | [(Lung cancer,is leading cause of,cancer death,1.0), (Lung cancer,be reduced through,targeted application,0.8420706941939625), (Lung cancer,be reduced through,targeted application of chemoprevention,0.8420706941939625), (Lung cancer,is,leading cause,1.0), (Lung cancer,be reduced through,application of chemoprevention,0.8420706941939625), (Lung cancer,is,cause,1.0), (Lung cancer,be,reduced,0.8420706941939625), (Lung cancer,be reduced through,application,0.8420706941939625), (Lung cancer,is cause of,cancer death,1.0)]  [(development,has,has linked,1.0), (development,has,has linked with high grade dysplasia,1.0), (development,has,has linked with persistent grade bronchial dysplasia,1.0), (development,has,has linked with persistent high grade bronchial dysplasia,1.0), (development,has,has linked with high grade bronchial dysplasia,1.0), (development,has,has linked with grade bronchial dysplasia,1.0), (development,has,has linked with grade dysplasia,1.0), (development,has,has linked with persistent grade dysplasia,1.0), (development,has,has linked with persistent high grade dysplasia,1.0)]  [(Bronchial histology,improved in,chemoprevention trial,1.0), (histology,improved in,chemoprevention trial,1.0), (histology,improved in,former smokers,1.0), (Bronchial histology,improved in,chemoprevention trial with prostacyclin analogue iloprost,1.0), (histology,improved in,chemoprevention trial with prostacyclin analogue iloprost,1.0), (chemoprevention trial,is with,prostacyclin analogue iloprost,1.0), (Bronchial histology,improved in,former smokers,1.0)]  [(Prostacyclin,acts through,peroxisome receptor gamma,1.0), (Prostacyclin,reverse,epithelial,1.0), (Prostacyclin,reverse,epithelial to transition,1.0), (epithelial,promote,signaling,1.0), (epithelial,promote,anti-cancer signaling,1.0), (Prostacyclin,acts through,peroxisome proliferator-activated receptor gamma,1.0), (Prostacyclin,acts through,PPARg,1.0), (Prostacyclin,reverse,epithelial to mesenchymal transition,1.0)]  [(EMT,provide,response markers for prostacyclin chemoprevention of lung cancer,1.0), (prostacyclin signaling pathway,provide,response markers for prostacyclin chemoprevention,1.0), (prostacyclin signaling pathway,provide,response markers for prostacyclin chemoprevention of lung cancer,1.0), (EMT,provide,response markers,1.0), (prostacyclin signaling pathway,provide,response markers,1.0), (EMT,provide,response markers for prostacyclin chemoprevention,1.0)]  [(RNA,was,extracted,1.0), (epithelial cells,were treated with,cigarette smoke condensate,1.0), (Human cells,were treated with,cigarette smoke condensate,1.0), (bronchial epithelial cells,were treated with,cigarette smoke condensate,1.0), (cells,CSC for,16 weeks,1.0), (epithelial cells,were,treated,1.0), (Human bronchial epithelial cells,were,treated,1.0), (bronchial epithelial cells,CSC for,16 weeks,1.0), (Human bronchial cells,were,treated,1.0), (Human epithelial cells,were,treated,1.0), (Human cells,CSC for,16 weeks,1.0), (Human epithelial cells,CSC for,16 weeks,1.0), (cells,were treated with,cigarette smoke condensate,1.0), (Human bronchial cells,were treated with,cigarette smoke condensate,1.0), (Human bronchial epithelial cells,CSC for,16 weeks,1.0), (epithelial cells,CSC for,16 weeks,1.0), (cells,were,treated,1.0), (bronchial epithelial cells,were,treated,1.0), (Human epithelial cells,were treated with,cigarette smoke condensate,1.0), (bronchial cells,were,treated,1.0), (bronchial cells,were treated with,cigarette smoke condensate,1.0), (Human cells,were,treated,1.0), (Human bronchial cells,CSC for,16 weeks,1.0), (Human bronchial epithelial cells,were treated with,cigarette smoke condensate,1.0), (bronchial cells,CSC for,16 weeks,1.0)]  [(Wild type,were,exposed to one week,1.0), (RNA,was,extracted,1.0), (Wild type,were,exposed to one week of cigarette smoke,1.0), (RNA,was extracted from,lungs,1.0), (Wild type,were,exposed,1.0)]  [(We,measured,potential markers of prostacyclin in models,1.0), (We,measured,potential markers of prostacyclin,1.0), (We,measured,potential markers in models,1.0), (potential markers,is in,models,1.0), (We,measured,potential markers,1.0)]  [(We,affected by,prostacyclin including PPARg,1.0), (We,affected by,prostacyclin,1.0), (We,inversely affected by,prostacyclin,1.0), (We,identified,panel,1.0), (We,inversely affected by,prostacyclin including PPARg,1.0)]  [(chemoprevention,is with,prostacyclin,1.0), (data,introduce,panel,1.0)]  [(Chemoprevention,is,promising,1.0)]  [(Identifying markers,is critical for,success in future trials,1.0), (markers,is critical for,success in future clinical trials of prostacyclin for lung cancer chemoprevention,1.0), (markers,is,critical,1.0), (markers,is critical for,success in future clinical trials,1.0), (Identifying markers,is critical for,success in future clinical trials of prostacyclin for lung cancer chemoprevention,1.0), (Identifying markers,is critical for,success in future clinical trials,1.0), (markers,is critical for,success,1.0), (Identifying markers,is critical for,success,1.0), (success,is in,future clinical trials of prostacyclin for lung cancer chemoprevention,1.0), (markers,is critical for,success in future trials of prostacyclin for lung cancer chemoprevention,1.0), (Identifying markers,is critical for,success in future clinical trials of prostacyclin,1.0), (markers,is critical for,success in future trials,1.0), (markers,is critical for,success in future clinical trials of prostacyclin,1.0), (Identifying markers,is critical for,success in future trials of prostacyclin for lung cancer chemoprevention,1.0), (Identifying markers,is,critical,1.0), (Identifying markers,is critical for,success in future trials of prostacyclin,1.0), (markers,is critical for,success in future trials of prostacyclin,1.0)]  The number of triplets '99 |
| Medical Words: Gene | 3 | … |
| … |  |  |

Abstract 7

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 107 | Lung, cancer, cause, cancer, death, burden, application, chemoprevention, development, lung, carcinoma, grade, dysplasia, histology, smokers, chemoprevention, trial, prostacyclin, analogue, iloprost, Prostacyclin, peroxisome, receptor, gamma, PPARg, transition, signaling, prostacyclin, signaling, pathway, EMT, response, markers, prostacyclin, chemoprevention, lung, cancer, cells, HBEC, cigarette, smoke, condensate, CSC, iloprost, weeks, CSC, weeks, CSC, weeks, weeks, CSC, iloprost, RNA, Wild, type, prostacyclin, synthase, PGIS, mice, week, cigarette, smoke, injection, urethane, RNA, lungs, markers, prostacyclin, efficacy, models, panel, markers, tobacco, carcinogens, prostacyclin, PPARg, 15pgdh, CES1, Cox-2, Ecadherin, Snail, Vimentin, CRB3, miR-34c, miR-221, data, panel, markers, interception, dysplasia, progression, chemoprevention, prostacyclin, Chemoprevention, approach, lung, cancer, mortality, population, markers, use, success, trials, prostacyclin, lung, cancer, chemoprevention, |
| POS:Verb | 35 | is, leading, be, reduced, targeted, has, been, linked, improved, acts, reverse, promote, hypothesized, provide, were, treated, followed, was, extracted, were, exposed, was, extracted, measured, identified, altered, affected, including, introduce, monitoring, is, reduce, Identifying, targeted, is, |
| NER : Name | 1 | Vimentin, |
| Triplet | 259 | [(Chronic pulmonary disease,is,chronic inflammatory disorder,1.0), (Chronic obstructive pulmonary disease,is inflammatory disorder with,increased incidence,1.0), (disease,is,disorder,1.0), (pulmonary disease,is,disorder,1.0), (Chronic disease,is chronic disorder with,incidence of lung cancer,1.0), (Chronic pulmonary disease,is chronic disorder with,incidence,1.0), (obstructive disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (disease,is chronic inflammatory disorder with,increased incidence,1.0), (Chronic disease,is chronic disorder with,incidence,1.0), (Chronic obstructive pulmonary disease,is disorder with,increased incidence,1.0), (obstructive disease,is chronic disorder with,increased incidence,1.0), (disease,is,chronic disorder,1.0), (Chronic obstructive disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic obstructive disease,is,disorder,1.0), (disease,is,inflammatory disorder,1.0), (Chronic pulmonary disease,is chronic disorder with,increased incidence of lung cancer,1.0), (disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic disease,is,disorder,1.0), (Chronic obstructive pulmonary disease,is disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is disorder with,increased incidence,1.0), (Chronic obstructive disease,is disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is,disorder,1.0), (disease,is disorder with,increased incidence,1.0), (obstructive pulmonary disease,is chronic disorder with,incidence,1.0), (obstructive disease,is chronic disorder with,incidence of lung cancer,1.0), (obstructive disease,is,inflammatory disorder,1.0), (Chronic obstructive disease,is disorder with,incidence,1.0), (obstructive disease,is disorder with,increased incidence,1.0), (pulmonary disease,is chronic disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is chronic disorder with,increased incidence of lung cancer,1.0), (Chronic disease,is,chronic inflammatory disorder,1.0), (pulmonary disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is chronic disorder with,incidence of lung cancer,1.0), (chronic inflammatory disorder,is with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is chronic disorder with,incidence of lung cancer,1.0), (obstructive disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive disease,is inflammatory disorder with,incidence,1.0), (disease,is chronic disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is disorder with,increased incidence of lung cancer,1.0), (obstructive disease,is inflammatory disorder with,increased incidence,1.0), (obstructive pulmonary disease,is inflammatory disorder with,incidence of lung cancer,1.0), (pulmonary disease,is chronic disorder with,increased incidence,1.0), (obstructive disease,is disorder with,incidence,1.0), (obstructive pulmonary disease,is chronic inflammatory disorder with,increased incidence,1.0), (obstructive disease,is,disorder,1.0), (Chronic pulmonary disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive disease,is,chronic disorder,1.0), (obstructive pulmonary disease,is inflammatory disorder with,incidence,1.0), (pulmonary disease,is,inflammatory disorder,1.0), (Chronic obstructive pulmonary disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic pulmonary disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic obstructive pulmonary disease,is chronic disorder with,incidence,1.0), (Chronic disease,is disorder with,increased incidence of lung cancer,1.0), (disease,is inflammatory disorder with,increased incidence,1.0), (Chronic obstructive pulmonary disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is,inflammatory disorder,1.0), (Chronic pulmonary disease,is inflammatory disorder with,incidence,1.0), (obstructive disease,is inflammatory disorder with,incidence,1.0), (Chronic disease,is,chronic disorder,1.0), (Chronic obstructive pulmonary disease,is disorder with,incidence,1.0), (pulmonary disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (obstructive disease,is disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is chronic inflammatory disorder with,incidence,1.0), (pulmonary disease,is inflammatory disorder with,increased incidence,1.0), (Chronic obstructive disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (Chronic disease,is chronic disorder with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is,disorder,1.0), (obstructive pulmonary disease,is disorder with,increased incidence of lung cancer,1.0), (Chronic disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic pulmonary disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive disease,is disorder with,increased incidence,1.0), (Chronic disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (pulmonary disease,is chronic disorder with,incidence of lung cancer,1.0), (disease,is chronic disorder with,increased incidence,1.0), (pulmonary disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic pulmonary disease,is,chronic disorder,1.0), (Chronic disease,is disorder with,incidence,1.0), (disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (pulmonary disease,is inflammatory disorder with,incidence,1.0), (Chronic disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic disease,is inflammatory disorder with,increased incidence,1.0), (obstructive pulmonary disease,is chronic disorder with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is disorder with,incidence of lung cancer,1.0), (disease,is disorder with,increased incidence of lung cancer,1.0), (pulmonary disease,is disorder with,incidence,1.0), (Chronic pulmonary disease,is chronic disorder with,increased incidence,1.0), (obstructive pulmonary disease,is chronic disorder with,increased incidence,1.0), (Chronic pulmonary disease,is inflammatory disorder with,increased incidence,1.0), (obstructive disease,is disorder with,increased incidence of lung cancer,1.0), (pulmonary disease,is disorder with,incidence of lung cancer,1.0), (disease,is disorder with,incidence of lung cancer,1.0), (Chronic obstructive disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive disease,is chronic disorder with,increased incidence of lung cancer,1.0), (Chronic disease,is,inflammatory disorder,1.0), (Chronic pulmonary disease,is chronic inflammatory disorder with,increased incidence,1.0), (disease,is,chronic,1.0), (Chronic obstructive disease,is chronic inflammatory disorder with,increased incidence,1.0), (pulmonary disease,is disorder with,increased incidence,1.0), (Chronic obstructive disease,is,chronic inflammatory disorder,1.0), (Chronic pulmonary disease,is,inflammatory disorder,1.0), (Chronic pulmonary disease,is chronic disorder with,incidence of lung cancer,1.0), (disease,is chronic disorder with,incidence of lung cancer,1.0), (pulmonary disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (disease,is disorder with,incidence,1.0), (Chronic pulmonary disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic pulmonary disease,is disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is chronic inflammatory disorder with,increased incidence,1.0), (Chronic obstructive disease,is,inflammatory disorder,1.0), (Chronic disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is,chronic disorder,1.0), (pulmonary disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive disease,is chronic disorder with,incidence,1.0), (Chronic disease,is disorder with,incidence of lung cancer,1.0), (Chronic disease,is inflammatory disorder with,incidence,1.0), (obstructive pulmonary disease,is disorder with,incidence,1.0), (obstructive disease,is,chronic disorder,1.0), (Chronic disease,is disorder with,increased incidence,1.0), (Chronic obstructive disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (obstructive disease,is chronic disorder with,incidence,1.0), (pulmonary disease,is,chronic disorder,1.0), (disease,is inflammatory disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (disease,is chronic disorder with,incidence,1.0), (pulmonary disease,is chronic inflammatory disorder with,increased incidence,1.0), (Chronic obstructive disease,is disorder with,incidence of lung cancer,1.0), (obstructive disease,is,chronic inflammatory disorder,1.0), (Chronic pulmonary disease,is disorder with,incidence,1.0), (pulmonary disease,is,chronic inflammatory disorder,1.0), (Chronic pulmonary disease,is,disorder,1.0), (obstructive pulmonary disease,is inflammatory disorder with,increased incidence,1.0), (Chronic obstructive pulmonary disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic pulmonary disease,is disorder with,incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is,chronic disorder,1.0), (Chronic obstructive disease,is chronic disorder with,increased incidence,1.0), (Chronic obstructive pulmonary disease,is inflammatory disorder with,incidence,1.0), (obstructive disease,is chronic inflammatory disorder with,increased incidence,1.0), (Chronic pulmonary disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (Chronic pulmonary disease,is disorder with,increased incidence,1.0), (obstructive pulmonary disease,is,chronic inflammatory disorder,1.0), (disease,is inflammatory disorder with,incidence,1.0), (Chronic disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic disease,is chronic disorder with,increased incidence,1.0), (obstructive disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (pulmonary disease,is disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is,inflammatory disorder,1.0), (pulmonary disease,is chronic disorder with,incidence,1.0), (Chronic obstructive pulmonary disease,is,chronic inflammatory disorder,1.0), (disease,is,inflammatory,1.0), (disease,is,chronic inflammatory disorder,1.0), (obstructive disease,is chronic disorder with,increased incidence of lung cancer,1.0), (obstructive disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive disease,is inflammatory disorder with,increased incidence,1.0), (Chronic obstructive disease,is chronic disorder with,incidence of lung cancer,1.0), (disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic disease,is chronic inflammatory disorder with,increased incidence,1.0), (obstructive disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic obstructive pulmonary disease,is chronic disorder with,increased incidence,1.0)]  [(emphysema component,confers,greatest proportion,1.0), (emphysema component,confers,proportion to lung cancer risk,1.0), (emphysema component,confers,proportion,1.0), (emphysema component,confers,greatest proportion to lung cancer risk,1.0)]  [(tumors,escape,immunity,1.0), (tumors,create,inflammatory conditions,1.0), (growth,is in,pre-established inflammatory microenvironments,1.0), (tumors,create,conditions,1.0)]  [(we,implanting cancer cells in,lungs of mice,1.0), (mice,is with,cigarette smoke-induced emphysema,1.0), (we,addressed issue In,study,1.0), (we,implanting,OVA-expressing cancer cells,1.0), (we,implanting cancer cells in,lungs,1.0), (we,implanting,cancer cells,1.0), (we,implanting cancer cells in,lungs of mice with cigarette emphysema,1.0), (we,addressed,issue,1.0), (we,implanting cancer cells in,lungs of mice with cigarette smoke-induced emphysema,1.0)]  [(Emphysema,augmented,growth of cancer cells,1.0), (Emphysema,augmented,growth,1.0)]  [(adoptive transfer,restore,their antitumor activity,1.0), (OVA-specific OTI T cells,showed,signs,1.0), (OVA-specific OTI T cells,showed,early signs of exhaustion,1.0), (OTI T cells,showed,signs,1.0), (OVA-specific OTI T cells,showed,signs of exhaustion,1.0), (OTI T cells,showed,early signs,1.0), (transfer,restore,their antitumor activity,1.0), (OTI T cells,showed,signs of exhaustion,1.0), (OTI T cells,showed,early signs of exhaustion,1.0), (transfer,is in,emphysema tumor hosts,1.0), (OVA-specific OTI T cells,showed,early signs,1.0)]  [(numbers,infiltrated,emphysema tumors,1.0), (Increased numbers,infiltrated,emphysema tumors,1.0), (CD11c,infiltrated,emphysema tumors,1.0), (IDO-positive CD11c,infiltrated,emphysema tumors,1.0)]  [(T cells,were unable Upon,adoptive transfer in hosts,1.0), (adoptive transfer,is in,immunocompetent hosts,1.0), (T cells,were unable Upon,adoptive transfer in immunocompetent hosts,1.0), (T cells,were unable Upon,adoptive transfer,1.0), (T cells,were,unable,1.0), (T cells,were unable Upon,transfer in immunocompetent hosts,1.0), (T cells,were unable Upon,transfer,1.0), (T cells,were unable Upon,transfer in hosts,1.0), (T cells,halt,tumor growth,1.0)]  [(they,upregulated via,oxidative mechanisms,0.006796423913394967), (they,upregulated via,oxidative stress-dependent mechanisms,0.006796423913394967), (they,upregulated PD-L1 IDO via,stress-dependent mechanisms,1.0), (they,upregulated PD-L1 IDO via,mechanisms,1.0), (they,upregulated PD-L1 IDO via,oxidative stress-dependent mechanisms,1.0), (DCs,exposed to,emphysema tumor microenvironment,0.683597900053659), (they,upregulated PD-L1 IDO via,oxidative mechanisms,1.0), (they,upregulated,PD-L1 IDO,1.0), (they,upregulated via,mechanisms,0.006796423913394967), (they,upregulated via,stress-dependent mechanisms,0.006796423913394967)]  [(T cell activation,increased in,emphysema tumor hosts,1.0), (T cell activation,increased upon,PD-L1 blockade,1.0), (T cell activation,increased in,emphysema tumor hosts in vivo,1.0), (T cell activation,increased upon,PD-L1 blockade in emphysema DC-T cell cocultures,1.0), (PD-L1 blockade,is in,emphysema DC-T cell cocultures,1.0)]  [(Analysis,showed,strong association between tomography-based emphysema of immunogenic processes,1.0), (Analysis,showed,association between computed emphysema of immunogenic processes,1.0), (Analysis,showed,association between emphysema of processes,1.0), (Analysis,showed,association between computed emphysema of processes,1.0), (Analysis,showed,strong association between computed emphysema of immunogenic processes,1.0), (Analysis,showed,strong association between computed emphysema,1.0), (Analysis,showed,association between tomography-based emphysema of processes,1.0), (Analysis,showed,strong association,1.0), (Analysis,showed,association between tomography-based emphysema of immunogenic processes,1.0), (Analysis,showed,association,1.0), (Analysis,showed,association between tomography-based emphysema,1.0), (Analysis,showed,strong association between computed tomography-based emphysema,1.0), (Analysis,showed,association between emphysema of immunogenic processes,1.0), (Analysis,showed,strong association between tomography-based emphysema,1.0), (Analysis,showed,strong association between emphysema,1.0), (Analysis,showed,association between computed tomography-based emphysema of immunogenic processes,1.0), (Analysis,showed,association between computed tomography-based emphysema,1.0), (Analysis,showed,strong association between computed tomography-based emphysema of processes,1.0), (Analysis,showed,strong association between tomography-based emphysema of processes,1.0), (Analysis,showed,strong association between emphysema of immunogenic processes,1.0), (Analysis,showed,association between emphysema,1.0), (Analysis,showed,strong association between computed tomography-based emphysema of immunogenic processes,1.0), (Analysis,showed,strong association between computed emphysema of processes,1.0), (Analysis,showed,association between computed emphysema,1.0), (Analysis,showed,association between computed tomography-based emphysema of processes,1.0), (Analysis,showed,strong association between emphysema of processes,1.0)]  [(suppression,links,disorder,1.0), (suppression,links disorder to,cancer,1.0), (suppression,Thus links,chronic disorder,1.0), (suppression,Thus links disorder with,clinical implications,1.0), (suppression,Thus links,emphysema,1.0), (suppression,links disorder with,implications,1.0), (suppression,Thus links disorder with,implications,1.0), (suppression,links,emphysema,1.0), (suppression,links disorder with,clinical implications,1.0), (suppression,links,chronic disorder,1.0), (suppression,Thus links,disorder,1.0), (suppression,Thus links disorder to,cancer,1.0)]  The number of triplets '259 |
| Medical Words: Gene | 3 | … |
| … |  |  |

Abstract 8

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 51 | disease, disorder, incidence, lung, cancer, emphysema, component, disease, proportion, lung, cancer, risk, tumors, conditions, immunity, responses, growth, cancer, cells, microenvironments, study, issue, cancer, cells, lungs, mice, cigarette, emphysema, Emphysema, growth, cancer, cells, effect, T, cells, OTI, T, cells, signs, exhaustion, transfer, emphysema, tumor, hosts, expansion, transfer, antitumor, activity, numbers, PD-L1, CD11c, |
| POS:Verb | 17 | is, increased, confers, create, escape, control, are, addressed, implanting, augmented, was, showed, was, sorting, failed, restore, Increased |
| NER : Name | 0 |  |
| Triplet | 290 | [(Epithelial-to-mesenchymal transition,is,initial step,0.9599077273661886), (transition,is,initial step,0.9599077273661886), (transition,is,step,0.9599077273661886), (Epithelial-to-mesenchymal transition,is,step,0.9599077273661886)]  [(widespread use,is,risk factor,1.0), (use,is still,major risk factor,1.0), (use,is still,risk factor for lung cancer,1.0), (widespread use,is still,risk factor for lung cancer,1.0), (widespread use,is,major risk factor,1.0), (use,is,risk factor for lung cancer,1.0), (use,is still,major risk factor for lung cancer,1.0), (widespread use,is,major risk factor for lung cancer,1.0), (widespread use,is still,major risk factor for lung cancer,1.0), (use,is,risk factor,1.0), (widespread use,is still,major risk factor,1.0), (smoking,is,risk factor,1.0), (smoking,is,major risk factor,1.0), (use,is,major risk factor,1.0), (use,is still,risk factor,1.0), (widespread use,is,risk factor for lung cancer,1.0), (smoking,is,major risk factor for lung cancer,1.0), (use,is,major risk factor for lung cancer,1.0), (smoking,is,risk factor for lung cancer,1.0), (smoking,is,major,1.0), (widespread use,is still,risk factor,1.0)]  [(lower levels,provide,safer alternative,1.0), (tobacco industry,has,Recently has transformed by introduction,1.0), (tobacco industry,has,has transformed,1.0), (lower levels,provide,alternative,1.0), (levels,provide,alternative,1.0), (levels,provide,safer alternative,1.0), (tobacco industry,has,Recently has transformed,1.0), (tobacco industry,has,has transformed by introduction,1.0)]  [(EMT,is in,A549 lung cancer cells,1.0)]  [(Human adenocarcinoma basal cells,were exposed from,popular product,0.8021767822641811), (adenocarcinoma basal cells,were exposed to,EC liquids,0.8021767822641811), (adenocarcinoma alveolar basal cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma epithelial cells,were exposed from,popular product,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were,exposed,0.8021767822641811), (adenocarcinoma epithelial cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were exposed from,popular product,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma epithelial cells,were,exposed,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (adenocarcinoma epithelial cells,were exposed from,popular product,0.8021767822641811), (Human adenocarcinoma alveolar cells,were,exposed to EC liquids from product,0.8021767822641811), (adenocarcinoma alveolar basal cells,were exposed from,popular product,0.8021767822641811), (adenocarcinoma alveolar basal cells,were,exposed to EC liquids from popular product,0.8021767822641811), (adenocarcinoma alveolar cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma epithelial cells,were,exposed to EC liquids from popular product,0.8021767822641811), (adenocarcinoma basal cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma basal cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were exposed from,popular product,0.8021767822641811), (Human adenocarcinoma basal cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma epithelial cells,were exposed to,EC liquids,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were exposed from,popular product,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma epithelial cells,were,exposed to EC liquids from product,0.8021767822641811), (Human adenocarcinoma cells,were exposed for,3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (adenocarcinoma cells,were exposed from,product,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were exposed to,EC liquids,0.8021767822641811), (adenocarcinoma epithelial cells,were,exposed from product for 3-8 days,0.8021767822641811), (adenocarcinoma basal cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma basal cells,were,exposed to EC liquids from popular product,0.8021767822641811), (adenocarcinoma alveolar basal cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma basal epithelial cells,were exposed from,popular product,0.8021767822641811), (adenocarcinoma epithelial cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma epithelial cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar cells,were,exposed,0.8021767822641811), (Human adenocarcinoma alveolar cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were exposed from,product,0.8021767822641811), (adenocarcinoma alveolar cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma epithelial cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma cells,were,exposed,0.8021767822641811), (Human adenocarcinoma epithelial cells,were exposed for,3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar cells,were exposed to,EC liquids,0.8021767822641811), (adenocarcinoma basal cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were,exposed from product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids from product,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were exposed for,3-8 days,0.8021767822641811), (Human adenocarcinoma basal cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were,exposed,0.8021767822641811), (adenocarcinoma cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were exposed from,product,0.8021767822641811), (adenocarcinoma cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma epithelial cells,were,exposed,0.8021767822641811), (adenocarcinoma cells,were,exposed to EC liquids from product,0.8021767822641811), (adenocarcinoma alveolar cells,were exposed from,popular product,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma alveolar cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (adenocarcinoma epithelial cells,were exposed from,product,0.8021767822641811), (adenocarcinoma basal cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma cells,were exposed to,EC liquids,0.8021767822641811), (adenocarcinoma basal epithelial cells,were exposed from,product,0.8021767822641811), (adenocarcinoma basal cells,were exposed for,3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma basal cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids from popular product,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma basal epithelial cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were exposed from,popular product,0.8021767822641811), (Human adenocarcinoma basal cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma basal cells,were exposed from,product,0.8021767822641811), (adenocarcinoma basal cells,were,exposed to EC liquids from product,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids from product,0.8021767822641811), (Human adenocarcinoma alveolar cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were,exposed,0.8021767822641811), (Human adenocarcinoma cells,were exposed from,popular product,0.8021767822641811), (adenocarcinoma alveolar basal cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (adenocarcinoma epithelial cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma basal cells,were exposed from,popular product,0.8021767822641811), (adenocarcinoma cells,were exposed to,EC liquids,0.8021767822641811), (adenocarcinoma alveolar cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal cells,were,exposed,0.8021767822641811), (Human adenocarcinoma epithelial cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids from product,0.8021767822641811), (Human adenocarcinoma alveolar cells,were,exposed,0.8021767822641811), (adenocarcinoma basal epithelial cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were,exposed,0.8021767822641811), (adenocarcinoma cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma epithelial cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma epithelial cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar cells,were exposed from,popular product,0.8021767822641811), (Human adenocarcinoma basal cells,were,exposed,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma basal cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma alveolar cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma epithelial cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal cells,were exposed for,3-8 days,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were,exposed to EC liquids from popular product,0.8021767822641811), (adenocarcinoma basal epithelial cells,were,exposed,0.8021767822641811), (Human adenocarcinoma cells,were exposed from,product,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were,exposed to EC liquids from product,0.8021767822641811), (adenocarcinoma epithelial cells,were,exposed to EC liquids from product,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were exposed from,popular product,0.8021767822641811), (Human adenocarcinoma cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma epithelial cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were exposed for,3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar cells,were,exposed to EC liquids from popular product,0.8021767822641811), (adenocarcinoma basal epithelial cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma basal cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma basal cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were,exposed from product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma alveolar cells,were,exposed to EC liquids from product,0.8021767822641811), (adenocarcinoma epithelial cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma basal cells,were,exposed,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal cells,were,exposed to EC liquids from product,0.8021767822641811), (adenocarcinoma alveolar cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma cells,were,exposed from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma epithelial cells,were exposed from,product,0.8021767822641811), (adenocarcinoma basal epithelial cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma alveolar basal epithelial cells,were exposed for,3-8 days,0.8021767822641811), (adenocarcinoma cells,were,exposed from product for 3-8 days,0.8021767822641811), (adenocarcinoma basal epithelial cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma epithelial cells,were,exposed from product for 3-8 days,0.8021767822641811), (adenocarcinoma basal epithelial cells,were,exposed to EC liquids from product,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were,exposed,0.8021767822641811), (adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (adenocarcinoma cells,were,exposed to EC liquids for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were,exposed to EC liquids from popular product,0.8021767822641811), (adenocarcinoma cells,were exposed from,popular product,0.8021767822641811), (adenocarcinoma basal epithelial cells,were exposed to,EC liquids,0.8021767822641811), (adenocarcinoma basal epithelial cells,were,exposed to EC liquids from popular product,0.8021767822641811), (Human adenocarcinoma alveolar cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (adenocarcinoma cells,were,exposed,0.8021767822641811), (Human adenocarcinoma basal epithelial cells,were exposed to,EC liquids,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were,exposed to EC liquids from product,0.8021767822641811), (Human adenocarcinoma alveolar basal cells,were exposed from,popular product,0.8021767822641811), (adenocarcinoma basal epithelial cells,were,exposed to EC liquids from product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar epithelial cells,were,exposed to EC liquids from product,0.8021767822641811), (Human adenocarcinoma alveolar cells,were,exposed from product for 3-8 days,0.8021767822641811), (adenocarcinoma basal cells,were,exposed from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma basal cells,were,exposed to EC liquids from popular product for 3-8 days,0.8021767822641811), (Human adenocarcinoma alveolar basal epithelial cells,were,exposed,0.8021767822641811), (Human adenocarcinoma cells,were,exposed to EC liquids from product,0.8021767822641811), (Human adenocarcinoma basal cells,were,exposed to EC liquids from product,0.8021767822641811)]  [(Live cell imaging,were,used,1.0), (machine learning/image processing algorithms,characterize,changes associated with EMT,1.0), (machine learning/image processing algorithms,characterize,changes associated,1.0), (cell imaging,were,used,1.0), (machine learning/image processing algorithms,characterize,changes,1.0)]  [(aerosols,Long-term exposure to,menthol,0.7286727551356617), (acquisition,loss of,cell-to-cell junctions,1.0), (aerosols,exposure to,menthol,0.7286727551356617), (upregulation,Long-term exposure of,A549 cells,0.7581534302535531), (acquisition,internalization of,E-cadherin,1.0), (fibroblast-like morphology,of acquisition is,internalization,1.0), (upregulation,EMT,characterized by acquisition,0.9783424583633715), (aerosols,upregulation of,other EMT markers,0.8360180563207444), (upregulation,EMT,characterized by acquisition of fibroblast-like morphology,0.9783424583633715), (upregulation,exposure to,menthol,0.7581534302535531), (aerosols,exposure of,A549 cells,0.7286727551356617), (upregulation,exposure of,A549 cells,0.7581534302535531), (upregulation,EMT,characterized by acquisition of morphology,0.9783424583633715), (upregulation,Long-term exposure to,menthol,0.7581534302535531), (aerosols,Long-term exposure of,A549 cells,0.7286727551356617), (upregulation,EMT,characterized,0.9783424583633715), (aerosols,upregulation of,EMT markers,0.8360180563207444)]  [(EMT,was,concurrent with plasma membrane to translocation of b-catenin,1.0), (EMT,was,concurrent with plasma membrane to nuclear translocation,1.0), (EMT,was,concurrent with plasma membrane to translocation of active b-catenin,1.0), (EMT,was concurrent to,nuclear translocation of b-catenin,1.0), (EMT,was concurrent to,translocation,1.0), (EMT,was concurrent with,plasma membrane,1.0), (EMT,was,concurrent with plasma membrane to nuclear translocation of b-catenin,1.0), (EMT,was concurrent to,translocation of active b-catenin,1.0), (EMT,was,concurrent with plasma membrane to nuclear translocation of active b-catenin,1.0), (EMT,was,concurrent,1.0), (EMT,was,concurrent with plasma membrane to translocation,1.0), (EMT,was concurrent to,translocation of b-catenin,1.0), (EMT,was concurrent to,nuclear translocation,1.0), (EMT,was concurrent to,nuclear translocation of active b-catenin,1.0)]  []  [(EMT,is,initial step leading to metastasis,1.0), (EMT,leading to,metastasis,0.780867064537945), (EMT,is,step leading to metastasis,1.0), (finding,has implications,step,1.0), (finding,has implications,initial step leading,1.0), (finding,has,significant implications,1.0), (critical finding,has implications,step leading,1.0), (finding,has,implications,1.0), (critical finding,has implications,step,1.0), (critical finding,has,significant implications,1.0), (EMT,is,step leading,1.0), (critical finding,has implications,step leading to metastasis,1.0), (EMT,is,initial step leading,1.0), (EMT,is,step,1.0), (finding,be at,risk for lung cancer,1.0), (finding,has implications,initial step leading to metastasis,1.0), (finding,has implications,step leading,1.0), (critical finding,has,implications,1.0), (EMT,is,initial,1.0), (critical finding,has implications,initial step leading to metastasis,1.0), (critical finding,has implications,initial step leading,1.0), (critical finding,be at,risk,1.0), (critical finding,be at,risk for lung cancer,1.0), (finding,has implications,initial step,1.0), (critical finding,has implications,initial step,1.0), (finding,has implications,step leading to metastasis,1.0), (finding,be at,risk,1.0), (EMT,is,initial step,1.0)]  The number of triplets '290 |
| Medical Words: Gene | 3 | … |
| … |  |  |

Abstract 9

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 29 | Cigarette, smoke, CS, risk, factor, development, lung, cancer, disease, COPD, transition, EMT, phenotypes, lung, cancer, COPD, MK-2206, pan, Akt, inhibitor, trials, tumors, doses, effects, agents, study, mechanism, MK-2206, EMT |
| POS:Verb | 15 | count for POS\_verb is 15: is, is, found, has, failed, administered, tolerated, has, been, shown, have, applied, targeted, investigated, working, |
| NER : Name | 0 |  |
| Triplet | 1 | John,was playing with,dog |
| Medical Words: Gene | 3 | … |
| … |  |  |

Abstract 10

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 31 | count for POS\_noun is 31: transition, EMT, step, metastasis, cancer, cells, death, smoking, risk, factor, lung, cancer, use, cigarettes, tobacco, industry, introduction, cigarettes, ECs, levels, carcinogens, alternative, ability, EC, liquids, aerosols, EMT, A549, lung, cancer, cells, |
| POS:Verb | 12 | count for POS\_verb is 12: is, enabling, leads, is, is, has, been, transformed, have, provide, investigate, induce, |
| NER : Name | 0 |  |
| Triplet | 1 | [(Glycosylation,is involved in,various diseases,1.0), (Glycosylation,is,involved,1.0), (interactions,are,plausible drug targets,1.0), (Glycosylation,is,profoundly involved,1.0), (Glycosylation,is profoundly involved in,various diseases,1.0), (Glycosylation,is profoundly involved in,diseases,1.0), (Glycosylation,is involved in,diseases,1.0)]  [(KS,is involved in,diseases,1.0), (Keratan sulfate,is,downregulated,1.0), (KS,is involved in,smoking-related diseases,1.0), (KS,is,involved,1.0), (Keratan sulfate,is downregulated by,cigarette smoking,1.0), (Keratan sulfate,is downregulated in,lungs,1.0), (Keratan sulfate,is,downregulated in lungs by cigarette smoking,1.0), (Keratan sulfate,is downregulated,suggesting,1.0)]  [(KS disaccharide,suppresses,lung inflammation,1.0), (sulfated KS disaccharide,suppresses,lung inflammation,1.0)]  [(Its activity,was comparable to,that,1.0), (Its activity,was,comparable,1.0), (Its anti-inflammatory activity,was comparable to,that,1.0), (Its activity,was comparable to,that of steroid,1.0), (Its anti-inflammatory activity,was comparable to,that of steroid,1.0), (Its anti-inflammatory activity,was,comparable,1.0)]  [(lectin receptor,expressed in,dendritic cells,0.6480871368721951), (C-type lectin receptor,expressed in,dendritic cells,0.6480871368721951), (langerin,was suggested As,possible mechanism,1.0), (langerin,was suggested,function,1.0), (lectin receptor,expressed in,cells,0.6480871368721951), (langerin,was suggested,function as L4 receptor,1.0), (langerin,was,suggested,1.0), (langerin,function as,L4 receptor,1.0), (C-type lectin receptor,expressed in,cells,0.6480871368721951)]  [(L4 derivatives,create,new ligands,1.0), (L4 derivatives,were,designed,1.0), (L4 derivatives,create,ligands,1.0), (L4 derivatives,create,new ligands with higher affinity,1.0), (L4 derivatives,create,new ligands with affinity,1.0), (L4 derivatives,create,ligands with affinity,1.0), (Oligomeric L4 derivatives,create,ligands,1.0), (Oligomeric L4 derivatives,create,new ligands with affinity,1.0), (Oligomeric L4 derivatives,were,designed,1.0), (new ligands,is with,higher affinity,1.0), (Oligomeric L4 derivatives,create,ligands with higher affinity,1.0), (Oligomeric L4 derivatives,create,ligands with affinity,1.0), (L4 derivatives,create,ligands with higher affinity,1.0), (L4 derivatives,were,chemically designed,1.0), (Oligomeric L4 derivatives,create,new ligands with higher affinity,1.0), (Oligomeric L4 derivatives,create,new ligands,1.0), (Oligomeric L4 derivatives,were,chemically designed,1.0)]  [(L4 oligomers,bound with,with affinity,1.0), (synthetic L4 oligomers,bound with,with 1000-fold higher affinity than L4 monomer,1.0), (compounds,are,drug candidates against COPD,1.0), (compounds,are,drug candidates,1.0), (compounds,are,effective drug candidates against COPD,1.0), (L4 oligomers,bound to,langerin,1.0), (synthetic L4 oligomers,bound with,with affinity,1.0), (L4 oligomers,bound with,with higher affinity,1.0), (compounds,are,effective drug candidates,1.0), (synthetic L4 oligomers,bound with,with affinity than L4 monomer,1.0), (synthetic L4 oligomers,bound to,langerin,1.0), (L4 oligomers,bound with,with 1000-fold higher affinity,1.0), (synthetic L4 oligomers,bound with,with 1000-fold higher affinity,1.0), (synthetic L4 oligomers,bound with,with higher affinity,1.0), (L4 oligomers,bound,suggesting,1.0), (synthetic L4 oligomers,bound with,with higher affinity than L4 monomer,1.0), (L4 oligomers,bound with,with higher affinity than L4 monomer,1.0), (synthetic L4 oligomers,bound,suggesting,1.0), (L4 oligomers,bound with,with 1000-fold higher affinity than L4 monomer,1.0), (L4 oligomers,bound with,with affinity than L4 monomer,1.0)] |
| Medical Words: Gene | 3 | … |
| … |  |  |

Outputs:

1. BioNLP

30111525|t|A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic.

30111525|a|BACKGROUND: There is strong evidence for the effectiveness of addressing tobacco use in health care settings. However, few smokers receive cessation advice when visiting a hospital. Implementing smoking cessation technology in outpatient waiting rooms could be an effective strategy for change, with the potential to expose almost all patients visiting a health care provider without preluding physician action needed. OBJECTIVE: The objective of this study was to develop an intervention for smoking cessation that would make use of the time patients spend in a waiting room by passively exposing them to a face-aging, public morphing, tablet-based app, to pilot the intervention in a waiting room of an HIV outpatient clinic, and to measure the perceptions of this intervention among smoking and nonsmoking HIV patients. METHODS: We developed a kiosk version of our 3-dimensional face-aging app Smokerface, which shows the user how their face would look with or without cigarette smoking 1 to 15 years in the future. We placed a tablet with the app running on a table in the middle of the waiting room of our HIV outpatient clinic, connected to a large monitor attached to the opposite wall. A researcher noted all the patients who were using the waiting room. If a patient did not initiate app use within 30 seconds of waiting time, the researcher encouraged him or her to do so. Those using the app were asked to complete a questionnaire. RESULTS: During a 19-day period, 464 patients visited the waiting room, of whom 187 (40.3%) tried the app and 179 (38.6%) completed the questionnaire. Of those who completed the questionnaire, 139 of 176 (79.0%) were men and 84 of 179 (46.9%) were smokers. Of the smokers, 55 of 81 (68%) said the intervention motivated them to quit (men: 45, 68%; women: 10, 67%); 41 (51%) said that it motivated them to discuss quitting with their doctor (men: 32, 49%; women: 9, 60%); and 72 (91%) perceived the intervention as fun (men: 57, 90%; women: 15, 94%). Of the nonsmokers, 92 (98%) said that it motivated them never to take up smoking (men: 72, 99%; women: 20, 95%). Among all patients, 102 (22.0%) watched another patient try the app without trying it themselves; thus, a total of 289 (62.3%) of the 464 patients were exposed to the intervention (average waiting time 21 minutes). CONCLUSIONS: A face-aging app implemented in a waiting room provides a novel opportunity to motivate patients visiting a health care provider to quit smoking, to address quitting at their subsequent appointment and thereby encourage physician-delivered smoking cessation, or not to take up smoking.

30111525 84 87 HIV Disease D015658

30111525 180 187 tobacco Species 4097

30111525 442 450 patients Species 9606

30111525 650 658 patients Species 9606

30111525 812 815 HIV Disease D015658

30111525 916 919 HIV Disease D015658

30111525 920 928 patients Species 9606

30111525 1218 1221 HIV Disease D015658

30111525 1328 1336 patients Species 9606

30111525 1375 1382 patient Species 9606

30111525 1587 1595 patients Species 9606

30111525 1767 1770 men Species 9606

30111525 1884 1887 men Species 9606

30111525 1898 1903 women Species 9606

30111525 1991 1994 men Species 9606

30111525 2005 2010 women Species 9606

30111525 2069 2072 men Species 9606

30111525 2083 2088 women Species 9606

30111525 2182 2185 men Species 9606

30111525 2196 2201 women Species 9606

30111525 2223 2231 patients Species 9606

30111525 2261 2268 patient Species 9606

30111525 2351 2359 patients Species 9606

30111525 2529 2537 patients Species 9606

30107977|t|Current and Former Smokers: Who Wants To Be Screened?

30107977|a|BACKGROUND: Lung cancer (LC) screening (LCS) with annual low-dose computed tomography scans has been seen to reduce the specific and overall mortality in selected populations. However, participation is key to successful screening programs. The EDIFICE (etude sur le d pistage des cancers et ses facteurs de compliance [survey on cancer screening and compliance factors]) nationwide observational surveys are used to assess behavior related to cancer screening programs in France. MATERIALS AND METHODS: Using comprehensive multivariate stepwise logistic regression analyses of data from current and former cigarette smokers, we sought to identify the explanatory factors associated with the intention to participate in an LCS program. RESULTS: Of the 1463 respondents with no personal history of cancer, 263 (36.4%) of the current cigarette smokers and 170 (26.3%) of the former cigarette smokers stated their willingness to participate in an LCS program. The explanatory factors differed between current cigarette smokers (already screened for LC: odds ratio [OR], 2.81; < 30 pack-years: OR, 2.69; intention to quit smoking: OR, 1.96; no social vulnerability: OR, 2.15) and former cigarette smokers (comorbidities: OR, 0.31). The usual eligibility criteria were not significantly explanatory. CONCLUSION: Our findings highlight the discrepancy that exists between target populations and individuals who actually intend to participate in a screening program for LC, with subsequent potential effects on the participation rates and, thus, on the efficacy of screening.

30107977 66 77 Lung cancer Disease D008175

30107977 79 81 LC Disease D008175

30107977 335 342 cancers Disease D009369

30107977 384 390 cancer Disease D009369

30107977 498 504 cancer Disease D009369

30107977 851 857 cancer Disease D009369

30107977 1100 1102 LC Disease D008175

30107977 1518 1520 LC Disease D008175

30052175|t|High rates of Mycobacterium fortuitum isolation in respiratory samples from Iranian patients with suspected tuberculosis: is it clinically important?

30052175|a|PURPOSE: Although Mycobacterium fortuitum (M. fortuitum) is not an organism rarely isolated from respiratory samples, its clinical importance is still not fully understood, which therefore prompted our current study. METHODOLOGY: We evaluated respiratory samples from 6800 patients with suspected tuberculosis from May 2014 to May 2016, for the detection of M. fortuitum using phenotypic and genotyping methods.Results/Key findings. Of the 40 patients with M. fortuitum lung disease, 35 had two or more positive culture results. The mean age of these 35 patients was 50.7 18.4 years, and 20 (57.1%) were men. Sputum (68.6%), haemoptysis (51.4%), cough (45.7%) and gastroesophageal disease (22.9%) were the major presenting symptoms. Cystic fibrosis, other bacterial lung diseases and lung cancer were the main underlying pulmonary diseases. Five patients (12.5%) were human immunodeficiency virus (HIV) positive. The most common chest X-ray findings were reticulonodular opacities (53.3%). Multivariate logistic regression analysis revealed that cigarette smoking history (OR 0.334, 95 % CI 0.125-0.843, P=0.048) and underlying lung disease (OR 0.393, 95 % CI 0.216-0.588, P=0.023) were significant predictors for positive M. fortuitum infection. CONCLUSION: These results demonstrated the high frequency of M. fortuitum in respiratory samples and that this bacterium causes transient infection or colonization in patients with underlying pulmonary conditions, such as cystic fibrosis and cigarette smoking-induced. Additionally, it appears that infection with M. fortuitum is particularly common and may be important in patients with HIV.

30052175 14 37 Mycobacterium fortuitum Species 1766

30052175 84 92 patients Species 9606

30052175 108 120 tuberculosis Disease D014376

30052175 168 191 Mycobacterium fortuitum Species 1766

30052175 193 205 M. fortuitum Species 1766

30052175 423 431 patients Species 9606

30052175 447 459 tuberculosis Disease D014376

30052175 508 520 M. fortuitum Species 1766

30052175 593 601 patients Species 9606

30052175 607 619 M. fortuitum Species 1766

30052175 620 632 lung disease Disease D008171

30052175 704 712 patients Species 9606

30052175 757 760 men Species 9606

30052175 817 841 gastroesophageal disease Disease D005764

30052175 886 901 Cystic fibrosis Disease D003550

30052175 909 932 bacterial lung diseases Disease D008171

30052175 937 948 lung cancer Disease D008175

30052175 974 992 pulmonary diseases Disease D008171

30052175 999 1007 patients Species 9606

30052175 1021 1049 human immunodeficiency virus Disease D015658

30052175 1051 1054 HIV Disease D015658

30052175 1090 1093 ray Species 255564

30052175 1283 1295 lung disease Disease D008171

30052175 1380 1392 M. fortuitum Species 1766

30052175 1393 1402 infection Disease D007239

30052175 1465 1477 M. fortuitum Species 1766

30052175 1542 1551 infection Disease D007239

30052175 1571 1579 patients Species 9606

30052175 1626 1641 cystic fibrosis Disease D003550

30052175 1703 1712 infection Disease D007239

30052175 1718 1730 M. fortuitum Species 1766

30052175 1778 1786 patients Species 9606

30052175 1792 1795 HIV Disease D015658

30051678|t|National Burden of Cancers Attributable to Secondhand Smoking in Indonesia

30051678|a|Background: The high prevalence of smokers in Indonesia is also increase the number of people as secondhandsmokers. Secondhand smoke causes many health problems, including cancer. Thus, Indonesia will bear large numbercancer burden of disease, but research on cancer related to secondhand smoking in Indonesia still does not exist.Therefore, this study aimed to determine the number of secondhand smoke attributable fractions (SAFs) of six cancers(lung, bladder, colorectal, stomach, pancreas and larynx) and burden of cancer caused by secondhand smoking inIndonesia using Disability Adjusted Life Years (DALYs) indicator. Material and Methods: This research was usingdescriptive epidemiological prevalence-based research design, with cancers prevalence data gained from Indonesianhealth assurance system database in 2016. The SAFs is calculated by combining both data of secondhand smokingprevalence and relative risk and the DALY indicator is calculated as the sum of years of life lost due to prematuremortality (YLL) and the equivalent healthy years lost due to disability (YLD). Results: Based on SAFs proportion,the highest SAFs among men were in pancreas cancer (80.20%), stomach cancer (79.54%) and laryngeal cancer(69.61%), whereas in women, pancreas cancer (78.95%), stomach cancer (78.26%) and bladder cancer (63.30%).Meanwhile, burden priorities for Indonesian men and woman were lung cancer (110,491), colorectal (68,131), andbladder cancer (39,140). Conclusions: In total, DALYs 6 cancer diseases due to secondhand smoke analyzed in thisstudy were 283,360 DALYs. Thus, the results of the research can be used as a basis for further policies making onnational cigarette prevention and control in Indonesia.

30051678 9 26 Burden of Cancers Disease D009369

30051678 162 168 people Species 9606

30051678 247 253 cancer Disease D009369

30051678 300 317 burden of disease Disease D004194

30051678 335 341 cancer Disease D009369

30051678 515 522 cancers Disease D009369

30051678 594 600 cancer Disease D009369

30051678 810 817 cancers Disease D009369

30051678 1216 1219 men Species 9606

30051678 1228 1243 pancreas cancer Disease D010190

30051678 1254 1268 stomach cancer Disease D009369

30051678 1282 1298 laryngeal cancer Disease D009369

30051678 1319 1324 women Species 9606

30051678 1326 1341 pancreas cancer Disease D010190

30051678 1352 1366 stomach cancer Disease D009369

30051678 1380 1394 bladder cancer Disease D001749

30051678 1448 1451 men Species 9606

30051678 1456 1461 woman Species 9606

30051678 1467 1478 lung cancer Disease D008175

30051678 1522 1528 cancer Disease D009369

30051678 1570 1585 cancer diseases Disease D009369

30050761|t|The epidemiology of lung cancer.

30050761|a|The incidence and mortality from lung cancer is decreasing in the US due to decades of public education and tobacco control policies, but are increasing elsewhere in the world related to the commencement of the tobacco epidemic in various countries and populations in the developing world. Individual cigarette smoking is by far the most common risk factor for lung carcinoma; other risks include passive smoke inhalation, residential radon, occupational exposures, infection and genetic susceptibility. The predominant disease burden currently falls on minority populations and socioeconomically disadvantaged people. In the US, the recent legalization of marijuana for recreational use in many states and the rapid growth of commercially available electronic nicotine delivery systems (ENDS) present challenges to public health for which little short term and no long term safety data is available.

30050761 20 31 lung cancer Disease D008175

30050761 66 77 lung cancer Disease D008175

30050761 141 148 tobacco Species 4097

30050761 244 251 tobacco Species 4097

30050761 394 408 lung carcinoma Disease D008175

30050761 430 454 passive smoke inhalation Disease D015208

30050761 499 508 infection Disease D007239

30050761 644 650 people Species 9606

30050761 690 699 marijuana Species 3483

30050761 794 802 nicotine Chemical D009538

30045935|t|Prostacyclin and EMT pathway markers for monitoring response to lung cancer chemoprevention.

30045935|a|Lung cancer is the leading cause of cancer death worldwide and global burden could be reduced through targeted application of chemoprevention. The development of squamous lung carcinoma has been linked with persistent, high grade bronchial dysplasia. Bronchial histology improved in former smokers in a chemoprevention trial with the prostacyclin analogue iloprost. ]=Prostacyclin acts through peroxisome proliferator-activated receptor gamma (PPARg) to reverse epithelial to mesenchymal transition and promote anti-cancer signaling. We hypothesized that the prostacyclin signaling pathway and EMT could provide response markers for prostacyclin chemoprevention of lung cancer. Human bronchial epithelial cells (HBEC) were treated with cigarette smoke condensate (CSC) or iloprost for two weeks, CSC for 16 weeks, or CSC for four weeks followed by four weeks of CSC and/or iloprost, and RNA was extracted. Wild type or prostacyclin synthase transgenic (PGIS) mice were exposed to one week of cigarette smoke or one injection of urethane, and RNA was extracted from the lungs. We measured potential markers of prostacyclin and iloprost efficacy in these models. We identified a panel of markers altered by tobacco carcinogens and inversely affected by prostacyclin, including PPARg, 15pgdh, CES1, Cox-2, Ecadherin, Snail, Vimentin, CRB3, miR-34c, and miR-221. These data introduce a panel of potential markers for monitoring interception of bronchial dysplasia progression during chemoprevention with prostacyclin. Chemoprevention is a promising approach to reduce lung cancer mortality in a high-risk population. Identifying markers for targeted use is critical for success in future clinical trials of prostacyclin for lung cancer chemoprevention.

30045935 0 12 Prostacyclin Chemical D011464

30045935 17 20 EMT Gene 3702

30045935 64 75 lung cancer Disease D008175

30045935 93 104 Lung cancer Disease D008175

30045935 129 141 cancer death Disease D009369

30045935 255 278 squamous lung carcinoma Disease D008175

30045935 323 342 bronchial dysplasia Disease D001982

30045935 427 439 prostacyclin Chemical D011464

30045935 449 457 iloprost Chemical D016285

30045935 461 473 Prostacyclin Chemical D011464

30045935 487 535 peroxisome proliferator-activated receptor gamma Gene 5468

30045935 537 542 PPARg Gene 5468

30045935 609 615 cancer Disease D009369

30045935 652 664 prostacyclin Chemical D011464

30045935 687 690 EMT Gene 3702

30045935 726 738 prostacyclin Chemical D011464

30045935 758 769 lung cancer Disease D008175

30045935 771 776 Human Species 9606

30045935 1012 1024 prostacyclin Chemical D011464

30045935 1046 1050 PGIS Gene 19223

30045935 1052 1056 mice Species 10090

30045935 1121 1129 urethane Chemical D014520

30045935 1202 1214 prostacyclin Chemical D011464

30045935 1287 1317 altered by tobacco carcinogens Disease D004408

30045935 1344 1356 prostacyclin Chemical D011464

30045935 1368 1373 PPARg Gene 5468

30045935 1389 1394 Cox-2 Gene 3205306

30045935 1533 1552 bronchial dysplasia Disease D001982

30045935 1593 1605 prostacyclin Chemical D011464

30045935 1657 1668 lung cancer Disease D008175

30045935 1796 1808 prostacyclin Chemical D011464

30045935 1813 1824 lung cancer Disease D008175

30037849|t|Cigarette Smoke-Induced Emphysema Exhausts Early Cytotoxic CD8+ T Cell Responses against Nascent Lung Cancer Cells.

30037849|a|Chronic obstructive pulmonary disease is a chronic inflammatory disorder with an increased incidence of lung cancer. The emphysema component of chronic obstructive pulmonary disease confers the greatest proportion to lung cancer risk. Although tumors create inflammatory conditions to escape immunity, the immunological responses that control growth of nascent cancer cells in pre-established inflammatory microenvironments are unknown. In this study, we addressed this issue by implanting OVA-expressing cancer cells in the lungs of mice with cigarette smoke-induced emphysema. Emphysema augmented the growth of cancer cells, an effect that was dependent on T cytotoxic cells. OVA-specific OTI T cells showed early signs of exhaustion upon transfer in emphysema tumor hosts that was largely irreversible because sorting, expansion, and adoptive transfer failed to restore their antitumor activity. Increased numbers of PD-L1- and IDO-positive CD11c+ myeloid dendritic cells (DCs) infiltrated emphysema tumors, whereas sorted emphysema tumor DCs poorly stimulated OTI T cells. Upon adoptive transfer in immunocompetent hosts, T cells primed by emphysema tumor DCs were unable to halt tumor growth. DCs exposed to the emphysema tumor microenvironment downregulated MHC class II and costimulatory molecules, whereas they upregulated PD-L1/IDO via oxidative stress-dependent mechanisms. T cell activation increased upon PD-L1 blockade in emphysema DC-T cell cocultures and in emphysema tumor hosts in vivo. Analysis of the transcriptome of primary human lung tumors showed a strong association between computed tomography-based emphysema scoring and downregulation of immunogenic processes. Thus, suppression of adaptive immunity against lung cancer cells links a chronic inflammatory disorder, emphysema, to cancer, with clinical implications for emphysema patients to be considered optimal candidates for cancer immunotherapies.

30037849 24 33 Emphysema Disease D004646

30037849 59 62 CD8 Gene 925

30037849 97 108 Lung Cancer Disease D008175

30037849 116 153 Chronic obstructive pulmonary disease Disease D029424

30037849 167 188 inflammatory disorder Disease D007249

30037849 220 231 lung cancer Disease D008175

30037849 237 246 emphysema Disease D004646

30037849 260 297 chronic obstructive pulmonary disease Disease D029424

30037849 333 344 lung cancer Disease D008175

30037849 360 366 tumors Disease D009369

30037849 477 483 cancer Disease D009369

30037849 621 627 cancer Disease D009369

30037849 650 654 mice Species 10090

30037849 684 693 emphysema Disease D004646

30037849 695 735 Emphysema augmented the growth of cancer Disease D009369

30037849 869 884 emphysema tumor Disease D009369

30037849 1036 1041 PD-L1 Gene 29126

30037849 1047 1050 IDO Gene 3620

30037849 1060 1065 CD11c Gene 3687

30037849 1109 1125 emphysema tumors Disease D009369

30037849 1142 1157 emphysema tumor Disease D009369

30037849 1260 1275 emphysema tumor Disease D009369

30037849 1300 1305 tumor Disease D009369

30037849 1333 1348 emphysema tumor Disease D009369

30037849 1447 1452 PD-L1 Gene 29126

30037849 1453 1456 IDO Gene 3620

30037849 1533 1538 PD-L1 Gene 29126

30037849 1551 1560 emphysema Disease D004646

30037849 1589 1604 emphysema tumor Disease D009369

30037849 1661 1666 human Species 9606

30037849 1667 1678 lung tumors Disease D008175

30037849 1741 1750 emphysema Disease D004646

30037849 1851 1862 lung cancer Disease D008175

30037849 1885 1906 inflammatory disorder Disease D007249

30037849 1908 1917 emphysema Disease D004646

30037849 1922 1928 cancer Disease D009369

30037849 1961 1970 emphysema Disease D004646

30037849 1971 1979 patients Species 9606

30037849 2020 2026 cancer Disease D009369

30032844|t|Akt/PKB signaling regulates cigarette smoke-induced pulmonary epithelial-mesenchymal transition.

30032844|a|OBJECTIVES: Cigarette smoke (CS) is a major risk factor for the development of lung cancer and chronic obstructive pulmonary disease (COPD). Epithelial-mesenchymal transition (EMT) is found in invasive or metastatic phenotypes in lung cancer and COPD. MK-2206, a pan Akt inhibitor, has failed in clinical trials for solid tumors when administered alone at tolerated doses, but it has been shown to have synergistic effects when applied with certain molecular targeted agents. In this study, we investigated the working mechanism of MK-2206 in CS-induced pulmonary EMT both in vivo and in vitro. MATERIALS AND METHODS: The expression of Akt, epithelial-mesenchymal transition (EMT) markers and signaling proteins were analyzed by immunohistochemistry, real-time PCR and Western blot in cigarette smoke extract (CSE)-treated pulmonary epithelia and CS-treated lung tissues in mice. RESULTS AND CONCLUSION: We demonstrated that exposure of the epithelium to CSE and exposure of the mice to CS can induce EMT by activating the Akt signaling pathway. Intragastric application of MK-2206 at a low dose (50 mg/kg) reversed the changes of the key indicators of EMT in the lungs of CS-exposed mice, including TGF-b1, a-SMA, vimentin, MMP-9, MMP-2, S100A4, collagen deposition, and E-cadherin. MK-2206 at a non-cytotoxic concentration (0.5 M) or Akt knockdown consistently reversed the changes of the key indicators of EMT in the pulmonary epithelia. Moreover, we found that the effects of Akt inhibition or knockdown on the CS/CSE-induced EMT acted via the TGF-b1/Akt/Smad/mTOR and Akt/P38 MAPK pathways. Taken together, our data offer a novel perspective on the molecular mechanism of Akt for CS-induced EMT. This finding may enhance the understanding of the mechanism behind the synergistic use of a low dose of MK-2206 to achieve antitumor efficacy with reduced adverse reactions in patients with lung cancer and COPD.

30032844 0 3 Akt Gene 11651

30032844 52 95 pulmonary epithelial-mesenchymal transition Disease D008171

30032844 176 187 lung cancer Disease D008175

30032844 192 229 chronic obstructive pulmonary disease Disease D029424

30032844 231 235 COPD Disease D029424

30032844 327 338 lung cancer Disease D008175

30032844 343 347 COPD Disease D029424

30032844 349 356 MK-2206 Chemical C548887

30032844 364 367 Akt Gene 11651

30032844 419 425 tumors Disease D009369

30032844 629 636 MK-2206 Chemical C548887

30032844 651 664 pulmonary EMT Disease D008171

30032844 733 736 Akt Gene 11651

30032844 882 905 cigarette smoke extract Disease 188890

30032844 907 910 CSE Disease 188890

30032844 920 939 pulmonary epithelia Disease D008171

30032844 971 975 mice Species 10090

30032844 1052 1055 CSE Disease 188890

30032844 1076 1080 mice Species 10090

30032844 1120 1123 Akt Gene 11651

30032844 1171 1178 MK-2206 Chemical C548887

30032844 1283 1287 mice Species 10090

30032844 1299 1305 TGF-b1 Gene 21803

30032844 1307 1312 a-SMA Gene 11475

30032844 1314 1322 vimentin Gene 22352

30032844 1324 1329 MMP-9 Gene 17395

30032844 1331 1336 MMP-2 Gene 17390

30032844 1338 1344 S100A4 Gene 20198

30032844 1371 1381 E-cadherin Gene 12550

30032844 1383 1390 MK-2206 Chemical C548887

30032844 1438 1441 Akt Gene 11651

30032844 1522 1541 pulmonary epithelia Disease D008171

30032844 1582 1585 Akt Gene 11651

30032844 1620 1623 CSE Disease 188890

30032844 1650 1656 TGF-b1 Gene 21803

30032844 1657 1660 Akt Gene 11651

30032844 1666 1670 mTOR Gene 56717

30032844 1675 1678 Akt Gene 11651

30032844 1679 1687 P38 MAPK Gene 26416

30032844 1779 1782 Akt Gene 11651

30032844 1907 1914 MK-2206 Chemical C548887

30032844 1979 1987 patients Species 9606

30032844 1993 2004 lung cancer Disease D008175

30032844 2009 2013 COPD Disease D029424

30032837|t|Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes.

30032837|a|OBJECTIVES: Epithelial-to-mesenchymal transition (EMT) is the initial step enabling the metastasis of cancer cells, which often leads to death. Although smoking is a major risk factor for lung cancer, there is still widespread use of conventional cigarettes. Recently, the tobacco industry has been transformed by the introduction of electronic cigarettes (ECs), which have lower levels of carcinogens and may provide a safer alternative. Here, we investigate the ability of EC liquids and aerosols to induce an EMT in A549 lung cancer cells. MATERIALS AND METHODS: Human adenocarcinoma alveolar basal epithelial cells (A549) were exposed to EC liquids and aerosols from a popular product for 3-8 days. Live cell imaging, EMT biomarker analysis, and machine learning/image processing algorithms were used to characterize changes associated with EMT. RESULTS: Long-term exposure of A549 cells to menthol or tobacco-flavored EC liquids or aerosols induced an EMT that was characterized by acquisition of a fibroblast-like morphology, loss of cell-to-cell junctions, internalization of E-cadherin, increased motility, and upregulation of other EMT markers. The EMT was concurrent with plasma membrane to nuclear translocation of active b-catenin. CONCLUSION: This is the first known study to show an EMT of lung cancer cells during exposure to EC products. Because an EMT is an initial step leading to metastasis, an intractable problem that often leads to patient death, this critical finding has significant implications for former or heavy cigarette smokers who are using EC and may be at risk for lung cancer or who may already have a lung tumor.

30032837 45 56 lung cancer Disease D008175

30032837 185 195 metastasis Disease D009362

30032837 199 205 cancer Disease D009369

30032837 234 239 death Disease D003643

30032837 285 296 lung cancer Disease D008175

30032837 370 377 tobacco Species 4097

30032837 621 632 lung cancer Disease D008175

30032837 663 668 Human Species 9606

30032837 669 683 adenocarcinoma Disease D000230

30032837 992 999 menthol Chemical D008610

30032837 1003 1010 tobacco Species 4097

30032837 1330 1339 b-catenin Gene 1499

30032837 1401 1412 lung cancer Disease D008175

30032837 1496 1506 metastasis Disease D009362

30032837 1551 1558 patient Species 9606

30032837 1559 1564 death Disease D003643

30032837 1695 1706 lung cancer Disease D008175

30032837 1733 1743 lung tumor Disease D008175

30025865|t|Implication of C-type lectin receptor langerin and keratan sulfate disaccharide in emphysema.

30025865|a|Glycosylation is profoundly involved in various diseases, and interactions between glycan binding proteins and their sugar ligands are plausible drug targets. Keratan sulfate (KS), a glycosaminoglycan, is downregulated in lungs by cigarette smoking, suggesting that KS is involved in smoking-related diseases, such as chronic obstructive pulmonary disease (COPD). We found that a highly sulfated KS disaccharide, L4, suppresses lung inflammation and is effective against COPD and its exacerbation in mouse models. Its anti-inflammatory activity was comparable to that of a steroid. As a possible mechanism, langerin, a C-type lectin receptor (CLR) expressed in dendritic cells, was suggested to function as an L4 receptor. Oligomeric L4 derivatives were chemically designed to create new ligands with higher affinity and activity. The synthetic L4 oligomers bound to langerin with over 1000-fold higher affinity than the L4 monomer, suggesting that these compounds are effective drug candidates against COPD and inflammatory diseases.

30025865 15 37 C-type lectin receptor Gene 12311

30025865 38 46 langerin Gene 246278

30025865 59 66 sulfate Chemical CHEBI:16189

30025865 83 92 emphysema Disease D004646

30025865 253 268 Keratan sulfate Chemical D007632

30025865 412 449 chronic obstructive pulmonary disease Disease D029424

30025865 451 455 COPD Disease D029424

30025865 522 539 lung inflammation Disease D011014

30025865 565 569 COPD Disease D029424

30025865 594 599 mouse Species 10090

30025865 667 674 steroid Chemical D013256

30025865 701 709 langerin Gene 246278

30025865 713 735 C-type lectin receptor Gene 12311

30025865 737 740 CLR Gene 12311

30025865 828 830 L4 Chemical

30025865 961 969 langerin Gene 246278

30025865 1097 1101 COPD Disease D029424

30025865 1106 1127 inflammatory diseases Disease D007249

Process finished with exit code 0

1. Wordnet

Counts:115

Verified words:cancer,leading,cause,cigarette,smoking,primary,cause,risk,across,same,number,are,at,greater,risk,are,at,lower,risk,developing,lung,specific,in,most,common,blood,modification,smoking,influence,internal,smoking,measured,by,urinary,nicotine,on,in,current,not,a,study,same,smoking,circulating,leukocyte,differ,by,

Counts:58

Verified words:strong,evidence,effectiveness,tobacco,use,in,health,care,few,receive,cessation,advice,visiting,a,smoking,cessation,technology,in,outpatient,waiting,rooms,be,an,effective,strategy,potential,expose,almost,all,visiting,a,health,care,provider,physician,action,

Counts:67

Verified words:cancer,screening,annual,tomography,reduce,specific,overall,mortality,in,selected,participation,key,successful,screening,sur,le,des,de,compliance,on,cancer,screening,compliance,nationwide,observational,are,used,assess,behavior,related,cancer,screening,in,

Counts:28

Verified words:not,an,organism,rarely,isolated,respiratory,clinical,importance,still,not,fully,therefore,current,

Counts:240

Verified words:high,prevalence,in,also,increase,number,people,as,smoke,many,health,will,bear,large,burden,but,research,on,cancer,related,secondhand,smoking,in,still,not,study,determine,number,secondhand,smoke,attributable,six,pancreas,burden,cancer,by,secondhand,smoking,using,research,epidemiological,research,prevalence,data,assurance,system,database,in,calculated,by,combining,both,data,secondhand,relative,risk,indicator,calculated,as,sum,years,life,lost,due,equivalent,healthy,years,lost,due,disability,on,men,in,pancreas,cancer,stomach,cancer,laryngeal,in,pancreas,cancer,stomach,cancer,bladder,cancer,burden,men,woman,lung,cancer,colorectal,cancer,6,cancer,due,secondhand,smoke,analyzed,in,research,can,be,used,as,a,basis,further,making,cigarette,prevention,control,in,

Counts:131

Verified words:incidence,mortality,lung,cancer,decreasing,in,due,public,education,tobacco,control,but,are,increasing,elsewhere,in,world,related,commencement,tobacco,epidemic,in,various,in,developing,cigarette,smoking,by,far,most,common,risk,factor,lung,other,include,passive,smoke,residential,occupational,infection,genetic,predominant,disease,burden,currently,falls,on,minority,socioeconomically,disadvantaged,recent,legalization,marijuana,recreational,use,in,many,rapid,growth,commercially,available,electronic,nicotine,delivery,present,public,health,little,short,term,no,long,term,safety,data,

Counts:245

Verified words:cancer,leading,cause,cancer,death,worldwide,global,burden,be,reduced,through,application,development,lung,carcinoma,linked,high,grade,bronchial,histology,improved,in,former,in,a,trial,analogue,acts,through,receptor,gamma,reverse,epithelial,transition,promote,signaling,pathway,provide,response,lung,bronchial,epithelial,treated,cigarette,smoke,condensate,or,two,16,or,four,by,four,type,or,exposed,one,week,cigarette,smoke,or,one,injection,measured,potential,efficacy,in,identified,a,panel,altered,by,tobacco,inversely,affected,by,data,introduce,a,panel,potential,monitoring,interception,bronchial,dysplasia,progression,a,promising,approach,reduce,lung,cancer,mortality,in,a,high-risk,use,critical,success,in,future,clinical,lung,cancer,

Counts:131

Verified words:obstructive,pulmonary,disease,a,chronic,inflammatory,disorder,an,increased,incidence,lung,emphysema,component,chronic,obstructive,pulmonary,disease,greatest,proportion,lung,cancer,create,inflammatory,conditions,escape,immunological,control,growth,nascent,cancer,in,inflammatory,are,addressed,issue,by,cancer,in,cigarette,augmented,growth,cancer,an,effect,dependent,on,cytotoxic,early,exhaustion,transfer,in,emphysema,18/09/10 20:35:56 INFO DAGScheduler: Job 0 finished: collect at WordNetSpark.scala:29, took 1.435117 s

18/09/10 20:35:56 INFO SparkContext: Invoking stop() from shutdown hook

18/09/10 20:35:56 INFO SparkUI: Stopped Spark web UI at http://DESKTOP-M4LGN3F:4040

tumor,largely,irreversible,adoptive,transfer,restore,antitumor,numbers,

Counts:90

Verified words:smoke,a,major,risk,factor,development,lung,cancer,chronic,obstructive,pulmonary,disease,transition,found,in,invasive,or,metastatic,in,lung,cancer,a,pan,in,clinical,solid,alone,at,but,it,have,synergistic,effects,applied,certain,molecular,working,mechanism,in,pulmonary,both,in,in,

Counts:81

Verified words:transition,initial,step,enabling,metastasis,cancer,often,smoking,a,major,risk,factor,lung,there,still,widespread,use,conventional,tobacco,industry,transformed,by,introduction,electronic,have,lower,may,provide,a,investigate,ability,induce,an,in,lung,cancer,18/09/10 20:35:56 INFO MapOutputTrackerMasterEndpoint: MapOutputTrackerMasterEndpoint stopped!

1. NLP

Abstract1:

count for POS\_noun is 46: Lung, cancer, cause, death, cigarette, smoking, cause, malignancy, risk, groups, number, cigarettes, Hawaiians, whites, risk, Americans, risk, lung, cancer, DNA, methylation, CpG, sites, AHRR, F2RL3, blood, modification, smoking, status, influence, smoking, dose, nicotine, equivalents, NE, DNA, methylation, smokers, study, smoking, dose, leukocyte, DNA, methylation, patterns, race,

count for POS\_verb is 19: is, leading, is, differs, smoked, compared, are, are, developing, is, associated, measured, has, been, investigated, has, evaluated, circulating, differ,

count for NER\_name is 0:

Abstract2:

count for POS\_noun is 24: evidence, effectiveness, tobacco, use, health, care, settings, smokers, cessation, advice, hospital, smoking, cessation, technology, outpatient, rooms, strategy, change, patients, health, care, provider, physician, action,

count for POS\_verb is 11: is, addressing, receive, visiting, Implementing, waiting, be, expose, visiting, preluding, needed,

count for NER\_name is 0:

Abstract3:

count for POS\_noun is 28: Lung, cancer, LC, screening, LCS, tomography, scans, mortality, populations, participation, screening, programs, EDIFICE, etude, sur, cancers, compliance, survey, cancer, screening, compliance, factors, surveys, behavior, cancer, screening, programs, France,

count for POS\_verb is 9: has, been, seen, reduce, selected, is, are, used, assess,

count for NER\_name is 0:

Abstract4:

count for POS\_noun is 8: Mycobacterium, fortuitum, M., fortuitum, organism, samples, importance, study,

count for POS\_verb is 5: is, isolated, is, understood, prompted,

count for NER\_name is 0:

Abstract5:

count for POS\_noun is 114: Background, prevalence, smokers, Indonesia, number, people, secondhandsmokers, smoke, health, problems, cancer, Indonesia, numbercancer, burden, disease, research, cancer, smoking, Indonesia, exist.Therefore, study, number, smoke, fractions, SAFs, cancers, lung, bladder, stomach, pancreas, larynx, burden, cancer, smoking, inIndonesia, Disability, Adjusted, Life, Years, DALYs, indicator, Material, Methods, research, research, design, cancers, prevalence, data, Indonesianhealth, assurance, system, database, SAFs, data, smokingprevalence, risk, DALY, indicator, sum, years, life, prematuremortality, YLL, years, disability, YLD, Results, SAFs, proportion, SAFs, men, pancreas, cancer, %, stomach, cancer, %, cancer, %, women, pancreas, cancer, %, stomach, cancer, %, bladder, cancer, %, burden, priorities, men, woman, lung, cancer, andbladder, cancer, Conclusions, total, DALYs, cancer, diseases, smoke, thisstudy, DALYs, results, research, basis, policies, cigarette, prevention, control, Indonesia,

count for POS\_verb is 27: is, increase, causes, including, bear, does, aimed, determine, caused, using, was, gained, is, calculated, combining, is, calculated, lost, lost, Based, were, were, analyzed, were, be, used, making,

count for NER\_name is 0:

Abstract6:

count for POS\_noun is 50: incidence, mortality, lung, cancer, US, decades, education, tobacco, control, policies, world, commencement, tobacco, countries, populations, world, cigarette, smoking, risk, factor, lung, carcinoma, risks, smoke, inhalation, radon, exposures, infection, susceptibility, disease, burden, minority, populations, people, US, legalization, marijuana, use, states, growth, nicotine, delivery, systems, ENDS, challenges, health, term, term, safety, data,

count for POS\_verb is 9: is, decreasing, are, increasing, developing, is, include, falls, is,

count for NER\_name is 0:

Abstract7:

count for POS\_noun is 107: Lung, cancer, cause, cancer, death, burden, application, chemoprevention, development, lung, carcinoma, grade, dysplasia, histology, smokers, chemoprevention, trial, prostacyclin, analogue, iloprost, Prostacyclin, peroxisome, receptor, gamma, PPARg, transition, signaling, prostacyclin, signaling, pathway, EMT, response, markers, prostacyclin, chemoprevention, lung, cancer, cells, HBEC, cigarette, smoke, condensate, CSC, iloprost, weeks, CSC, weeks, CSC, weeks, weeks, CSC, iloprost, RNA, Wild, type, prostacyclin, synthase, PGIS, mice, week, cigarette, smoke, injection, urethane, RNA, lungs, markers, prostacyclin, efficacy, models, panel, markers, tobacco, carcinogens, prostacyclin, PPARg, 15pgdh, CES1, Cox-2, Ecadherin, Snail, Vimentin, CRB3, miR-34c, miR-221, data, panel, markers, interception, dysplasia, progression, chemoprevention, prostacyclin, Chemoprevention, approach, lung, cancer, mortality, population, markers, use, success, trials, prostacyclin, lung, cancer, chemoprevention,

count for POS\_verb is 35: is, leading, be, reduced, targeted, has, been, linked, improved, acts, reverse, promote, hypothesized, provide, were, treated, followed, was, extracted, were, exposed, was, extracted, measured, identified, altered, affected, including, introduce, monitoring, is, reduce, Identifying, targeted, is,

count for NER\_name is 1: Vimentin,

Abstract8:

count for POS\_noun is 51: disease, disorder, incidence, lung, cancer, emphysema, component, disease, proportion, lung, cancer, risk, tumors, conditions, immunity, responses, growth, cancer, cells, microenvironments, study, issue, cancer, cells, lungs, mice, cigarette, emphysema, Emphysema, growth, cancer, cells, effect, T, cells, OTI, T, cells, signs, exhaustion, transfer, emphysema, tumor, hosts, expansion, transfer, antitumor, activity, numbers, PD-L1, CD11c,

count for POS\_verb is 17: is, increased, confers, create, escape, control, are, addressed, implanting, augmented, was, showed, was, sorting, failed, restore, Increased,

count for NER\_name is 0:

Abstract9:

count for POS\_noun is 29: Cigarette, smoke, CS, risk, factor, development, lung, cancer, disease, COPD, transition, EMT, phenotypes, lung, cancer, COPD, MK-2206, pan, Akt, inhibitor, trials, tumors, doses, effects, agents, study, mechanism, MK-2206, EMT,

count for POS\_verb is 15: is, is, found, has, failed, administered, tolerated, has, been, shown, have, applied, targeted, investigated, working,

count for NER\_name is 0:

Abstract10:

count for POS\_noun is 31: transition, EMT, step, metastasis, cancer, cells, death, smoking, risk, factor, lung, cancer, use, cigarettes, tobacco, industry, introduction, cigarettes, ECs, levels, carcinogens, alternative, ability, EC, liquids, aerosols, EMT, A549, lung, cancer, cells,

count for POS\_verb is 12: is, enabling, leads, is, is, has, been, transformed, have, provide, investigate, induce,

count for NER\_name is 0:

Triplets:

[(tobacco use,is in,health care settings,1.0)]

[(few smokers,However receive,cessation advice,1.0), (smokers,visiting,hospital,1.0), (few smokers,visiting,hospital,1.0), (few smokers,receive,cessation advice,1.0), (smokers,However receive,cessation advice,1.0), (smokers,receive,cessation advice,1.0)]

[(could effective strategy,is with,potential expose,1.0)]

[(patients,passively exposing,them,1.0), (patients,exposing,them,1.0), (intervention,is in,waiting room of HIV outpatient clinic,1.0), (patients,spend in,room,1.0), (patients,spend in,waiting room,1.0)]

[(their face,would look to,15 years in future,1.0), (15 years,is in,future,1.0), (their face,would look to,15 years,1.0)]

[(We,placed tablet,app running on table in middle of waiting room of our HIV outpatient clinic,1.0), (app,running on,table in middle of room,1.0), (We,placed tablet,app running,1.0), (We,placed tablet,app running on table in middle,1.0), (app,running on,table in middle,1.0), (table,is in,middle of waiting room of our HIV outpatient clinic,1.0), (app,running on,table in middle of waiting room of our HIV outpatient clinic,1.0), (We,placed tablet,app running on table in middle of room,1.0), (We,placed tablet,app running on table,1.0), (We,placed tablet,app running on table in middle of waiting room,1.0), (app,running on,table in middle of waiting room,1.0), (app,running on,table,1.0), (We,placed,tablet,1.0), (app,running on,table in middle of room of our HIV outpatient clinic,1.0), (We,placed tablet,app running on table in middle of room of our HIV outpatient clinic,1.0)]

[(Those,complete,questionnaire,1.0), (Those,were,asked,1.0)]

[(RESULTS,visited During,19-day period,1.0)]

[(their,doctor,men,1.0)]

[(464 patients,of total is,62.3 %,1.0), (289,of total is,62.3 %,1.0)]

[(face-aging app,address,quitting at their appointment,1.0), (face-aging app,implemented in,waiting room,0.46308092758132374), (app,address,quitting at their subsequent appointment,1.0), (app,implemented in,waiting room,0.46308092758132374), (app,address,quitting,1.0), (face-aging app,address,quitting at their subsequent appointment,1.0), (patients,visiting,health care provider,0.7169231644655831), (app,address,quitting at their appointment,1.0), (face-aging app,implemented in,room,0.46308092758132374), (face-aging app,address,quitting,1.0), (app,implemented in,room,0.46308092758132374)]

The number of triplets '48

[(Lung cancer screening,reduce,specific mortality in populations,1.0), (Lung cancer screening,is with,annual low-dose computed tomography scans,1.0), (specific mortality,is in,selected populations,1.0), (Lung cancer screening,reduce,specific mortality,1.0), (Lung cancer screening,reduce,mortality,1.0), (annual low-dose computed tomography scans,with screening is,LCS,1.0), (Lung cancer screening,reduce,specific mortality in selected populations,1.0), (Lung cancer screening,reduce,mortality in populations,1.0), (Lung cancer screening,reduce,mortality in selected populations,1.0)]

[(participation,is key to,screening programs,1.0), (participation,is key to,successful screening programs,1.0), (participation,is,key,1.0), (participation,However is key to,successful screening programs,1.0), (participation,is,However key,1.0), (participation,However is key to,screening programs,1.0)]

[(EDIFICE nationwide surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE nationwide surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE nationwide surveys,assess,behavior,1.0), (behavior,related to,cancer screening programs in France,0.586438403410859), (EDIFICE nationwide observational surveys,assess,behavior,1.0), (EDIFICE nationwide observational surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE observational surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE nationwide observational surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE observational surveys,are,used,1.0), (behavior,related to,cancer screening programs,0.586438403410859), (EDIFICE observational surveys,assess,behavior related to cancer screening programs in France,1.0), (cancer screening programs,is in,France,1.0), (EDIFICE nationwide surveys,are,used,1.0), (EDIFICE nationwide surveys,assess,behavior related,1.0), (EDIFICE surveys,are,used,1.0), (EDIFICE surveys,assess,behavior,1.0), (EDIFICE observational surveys,assess,behavior,1.0), (EDIFICE nationwide observational surveys,are,used,1.0), (EDIFICE nationwide observational surveys,assess,behavior related,1.0), (EDIFICE surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE surveys,assess,behavior related,1.0), (EDIFICE observational surveys,assess,behavior related,1.0)]

[(we,identify,explanatory factors,1.0), (we,identify,factors associated,1.0), (we,identify,factors associated with intention participate,1.0), (we,identify,explanatory factors associated with intention participate in LCS program,1.0), (we,identify,explanatory factors associated,1.0), (we,identify,explanatory factors associated with intention participate,1.0), (we,identify,factors,1.0), (we,identify,factors associated with intention participate in LCS program,1.0)]

[(1463 respondents,is with,personal history of cancer,1.0), (former cigarette smokers,of 170 is,26.3 %,1.0), (current cigarette smokers,of 263 is,36.4 %,1.0)]

[(explanatory factors,differed between,current cigarette smokers,1.0), (explanatory factors,differed between,cigarette smokers,1.0), (factors,differed between,cigarette smokers,1.0), (factors,differed between,current cigarette smokers,1.0)]

The number of triplets '53